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1Abstract
Background: Although the goal of achieving ‘as close as possible to universal access to
treatment for all those who need it by 2010 has been stated in 2005(1), the implementation of
successful treatment programs remain a challenge in Sub-Saharan Africa. One of the major
challenges in AIDS treatment programs is adherence. There is little evidence as to why some
ARV users do not achieve optimal adherence rates in ART centers in Ethiopia.
Study Objectives: The objective of this study was to identify structural and patient-related
factors to ART adherence and to assess the quality of the process involved in providing ART
services for patients attending the selected sites.
Study Methods: The study utilized a qualitative study design using semi-structured interviews,
in-depth interviews and observational methods
Results: Cost of transport to ART centers, lack of adequate food/nutrition, and stigma and
discrimination were among the factors which adversely affect adherence. Missing and/or
delaying in taking the ARVs doses due to work load, travel, forgetfulness and lack of disclosure
were among the factors contributing to poor adherence. Disclosure supports adherence and most
of the ARV users had disclosed their HIV positive status at least to one family member. On the
other hand, most of the clients expressed their satisfaction with the new fixed dose combination
(FDC) ARVs regimen, by stating that it is easier to take, so that it contributes to adhere better
compared to the previous ARVs regimen.
Conclusion and recommendations: Lack of food and stigma and discrimination are among the
major factors affecting adherence. Re-designing food support programs and enhanced social
mobilization are among the recommendations.
21. Introduction
Although the goal of achieving ‘as close as possible to universal access to treatment for
all those who need it by 2010 has been stated in 2005(1), the implementation of successful
treatment programs remain a challenge in Sub-Saharan Africa.
One of the major challenges in AIDS treatment programs is adherence. There is little
evidence as to why some ARV users do not achieve optimal adherence rates or about how to
improve adherence support in resource-poor settings (2). Different reports on sub-optimal
adherence to ART in developed countries indicate that the key factors are patient- and treatment
related, including substance and alcohol abuse, forgetfulness because of complexity of dosing
regimen and ‘pill burden’, financial constraints, dietary restrictions and side-effects (3, 4).
AIDS is one of a serious public health problem in Ethiopia; the first evidence of HIV
infection in this country is seen in 1984 and the first two AIDS cases were reported to MOH in
1986. HIV 1 subtype C is the dominant variant. ANC based HIV Surveillance started in 1989,
since then the prevalence is reported every two years. In 2005, DHS had also conducted
population based HIV prevalence study. There were some methodological issues that were
associated with the use of either the ANC estimates or the DHS estimates to represent the
national burden of disease; thus the Federal Ministry of Health and the HIV/AIDS Prevention
and Control Office (HAPCO) decided to derive a single point estimate taking into consideration
relevant data from both system; which is now commonly referred as ‘single point estimate’.
According to a single point HIV prevalence estimate (5), in 2009 about 1,116,216 people are
estimated to live with HIV with HIV prevalence of 2.3%.
Even though ART Service Started in July, 2003, free based ART program started in
March 2005. As of March 9, 2009 national ART report; there are 441 operational ART sites both
3in the hospitals and health centers. The cumulative ever enrolled at the end of the month is
339,635. New persons started during the month are 4228 and the cumulative ever started at the
end of the month are 189,267. Total currently on ART are only 139,494, meaning that 49,773
(26.30%) are lost-to-follow-up. Anecdotal evidence shows that over half of lost-to-follow-up
individuals have died (6). The pediatric cases currently on ART are 7716 (5.53%). Cases on the
first line ARV regimen are 98.7% and 1.28% are on the second line regimen.
As ART is one of the most expensive health interventions in Ethiopia with a very serious danger
of developing resistance if not properly managed; the need for continuous monitoring of the
program is imperative. Strict adherence to the treatment regimen is absolutely important.
Adherence is a major key factor for the success of ART program.
There are only few qualitative studies on adherence done in developing countries. So research is
urgently needed to determine patient-important factors for adherence in developing world
settings. Studying the factors that facilitate adherence and barriers for adherence is one of the
crucial professional obligations; especially in resource-constrained countries. This study will
provide some useful insight to the factors affecting adherence in the Ethiopian context.
42: Literature Review
Until 1995, treatment for HIV-1 infection consisted mainly of single-drug and dual-drug
therapy regimens that provided limited success. With the introduction of protease inhibitors
(PIs), dramatic declines in HIV viral loads and AIDS-associated events were achieved. This
prompted at an international level revision of existing guidelines for the treatment of AIDS. At
present, a combination therapy involving agents from three classes of antiretroviral agents—
nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs), and PIs—form the
basis of potent regimens known as ART (antiretroviral therapy). The combination ART regimens
substantially improved the success rate of AIDS treatment throughout the world. The main
biological and clinical goals of ART is suppression of viral replication, restoration of the
immune response, a halt in the progression of disease, increased survival rates, reduced
morbidity and a better quality of life. In countries where access to this level of care is available,
AIDS-related mortality and morbidity have significantly declined (7).
In most ART programs adherence level of less than 95 percent is regarded as failure to
treatment (8). Adherence at lesser rates fosters development of virus mutations; even adherence
level of 80 to 90 percent was reported to be associated with high resistance (9, 10). The
possibility of quick development of a resistant virus is worrisome because it limits treatment
options for the patient. Ideally, patients need to be flawless for a maximum and sustainable
suppression of HIV viral replication to below the level of detection. To achieve that goal an
adherence level of 95% or more is desired.
Adherence to ART requires taking all pills in the correctly prescribed doses, at the right
time and in the right way (10). It involves the following elements: taking all the medicines which
5make up the ARV combination in the correct quantities; taking pills at the right times; ensuring
that medications are taken with or without food, according to the instructions; and checking for
interaction with any other medication or drugs. The best response to ART is seen when
adherence is 100% (11).
Although efforts are made to varying degree in ART programs to maximize adherence
level of patients, it is obvious that some people with AIDS do not manage to achieve such high
levels of adherence. Sub optimal adherence to ART cause failure to suppress viral replication
completely, and inevitably leads to the selection of drug resistant strains limiting the
effectiveness of therapy (12). In addition to leading to disease progression this may result in the
development and transmission of drug resistant viruses which can not be treated with first line
(lower cost) medicines. This will require treatment with second and or third line medicines,
which are more expensive, associated with many side effects and are complex to manage (13).
Measuring adherence in the most accurate and reliable way is one of the most critical
issues for researchers. The lack of gold standard for assessing the validity of the various methods
of adherence measured used is the main challenge (14). The many methods employed by the
different studies include, pill counting, electronic drug monitoring (EDM), pharmacy refill
records, biochemical markers and other self reporting techniques such as visual analogue and
recall methods. The relative accuracy of adherence measures ranks from physician assessment
and self assessment being the least accurate, to pill counting being intermediate, and EDM being
the most accurate (15).
Adherence is affected by many factors related to either individual characteristics or to the
way the health system is organized. Age may influence adherence; studies have found that, with
the exception of the most elderly adherence increases with age. In two studies associated with
6ART adherence sub-optimal adherence showed a positive correlation with being younger (16).
A lower level of general education and poorer literacy may impact negatively on patients’ ability
to adhere, while a higher level of education has a positive impact (17).
Studies conducted in Africa reveal that the cost of medication is one of the most
significant barriers to treatment adherence. In countries, where ART was provided at its cost or
non-subsidized, patients would find to adhere to prescribed regimen very difficult (3,18).  Even
in countries where medication is free of charge, the cost of clinic visits may stretch an already
meager budget. In resource poor countries many people live below the poverty line and there is
often no medical insurance or disability pension for people living with HIV (19). Living alone
and lack of social support network have been associated with an increase in suboptimal
adherence (20, 33). Not living alone, having a partner, social or family support, peer interaction
and relationships are associated with optimal adherence (21).
Almost all of those who are currently on ART are on a regimen of three or more ARVs
(22). The likelihood of a patient’s adherence to a given regimen declines with poly pharmacy,
the frequency of dosing, the frequency and severity of side effects, and the complexity of the
regimen (19). Drug hypersensitivity is common in patients with HIV and regimen associated
toxicity is a common predictor of and reason for sub optimal adherence. Although these side
effects usually subside after the first few weeks of therapy, for some people they persist. The
anticipation and fear of side effects also have an impact on adherence. Poor adherence has also
been associated with patients’ desire to avoid embarrassing side effects (like sweating) in certain
situations such as on a date or at a job interview (23). For people on ART, a typical combination
of medicines consists of there ARVs, plus other medication to prevent opportunistic infections.
This can result in a high pill burden taking medicine three times a day, dietary and dosing
7idiosyncrasies, large capsules or tablets and specific storage instructions. The complexity of this
regimen may have a significant impact on a patient’s ability to adhere (24). Additional
medications taken for symptomatic relief (such as analgesics, cough remedies and other common
treatments) in patients with advanced disease further add to the pill burden and toxicity.
Recently, efforts to solve the problems related to poly pharmacy are intensified and resulted in
the production of some single pill fixed dose combination.
Dietary restrictions also add to the complexity of ART and often require adjustments in
lifestyle. Patients can find their meal schedule compromised by ARVs that need to be taken on
an empty stomach. This can be particularly difficult if workmates, family or friends are unaware
of the patients HIV status (21). Complicated regimens with rigid dosing intervals may also
interrupt sleep. The physical aspects of a particular medication (for example taste, size or
formulation) may also affect a patient’s ability to adhere. The physical state of the patient and the
clinical stage of the disease at the time of treatment initiation also affect the level adherence (25).
It is also important to note that mere increase in CD4 cell counts may not indicate proper
adherence (15, 26).  Having HIV/AIDS is a very distressful condition and patients may
experience some mental health problems and AIDS related dementia (AIDS Dementia Complex)
(28, 29); patients with depression and severe anxiety are more likely to have sub optimal
adherence (27).
The belief and understanding of patients about their illness and the effectiveness of the
treatment can significantly influence adherence. A good level of understanding about HIV, and a
belief that ART is effective in prolonging life facilitate better adherence (30). The proximity of
the health facility providing ART to home of patients as well as the frequency of clinic visits,
8clinic waiting time, confidentiality, pharmacy dispensing practices, and the provider-client
interaction influence adherence favorably or not (21, 22, 31).
The conceptual framework (Figure 1) identifies service factors, patient factors,
socioeconomic and cultural factors leading directly and indirectly to sub optimal adherence to
ARVs. This study aimed to identify the most critical factors that influence adherence in public
ART service providing facilities.
9Figure 1: The conceptual framework of factors leading to sub-optimal adherence to ARVs
Source: Adopted from “from access to adherence: the challenges of antiretroviral treatment” a
study paper by university of Amsterdam, WHO and Royal Tropical Institute, 2005.
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3: Study Objectives
3.1 General objective
The purpose of this study is to identify possible factors influencing adherence to ART among
adults in Addis Ababa.
3.2 Specific Objectives
 To identify structural and patient-related factors to ART adherence.
 To assess the quality of the process involved in providing ART services for patients
attending the selected sites.
11
4: Methodology
4.1:   Study Area (Description of study sites)
The study was conducted in two health facilities providing ART. The first study site was
Zewditu memorial referral hospital, which is located in the capital city of Ethiopia, Addis Ababa.
When the study was conducted there were about 5320 ART clients enrolled in the hospital. The
second study site was Bole health center, which is located also in Addis Ababa. When the study
was conducted there were about 1000 ART clients enrolled in this health facility.
4.2: Study Design
The study utilized a qualitative study design using semi-structured interviews, in-depth
interviews and observations.
4.3: Study Population
The study population included
 ARV users from two health care facilities who met the criterion of being on ART for at
least three months
 Staff at the two health care facilities who were involved in counseling and providing
ARV medicines (e.g., Doctors,  Health officers, nurses) and the pharmacists who were
dispensing and stocking drugs.
 Key informants were identified from among the communities to which the ARV users
belong. (e.g. Leaders of PLH associations)
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4.4: Inclusion and Exclusion Criteria for Interviewees
Inclusion criteria:
Patients/Clients and Key Informants
- Adult, 18 years or over and willing to participate in the study.
- On ART for at least three months*.
Health care workers
- Staff working at the ART clinic and willing to participate in the study
- Well informed about ARV users
- Working at the ART clinic for at least one month
Exclusion criteria
Patients/Clients and Key Informants
- Not willing to be interviewed
- Below age 18 years
- Not on ARV treatment
Health care workers
- Not willing to be interviewed
- Working at the ART clinic for less than one month
- Not directly interacting with ARV patients.
* We included only those who were on ART for at least three months with the assumption that,
those who took ARVs for a duration of less than three months may not face adherence problems
as much as those who took ARVs for a longer period.
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4.5   Sample Size and Sampling
The sample size for the study was not fixed at the beginning of the study.  It was left to be
decided by the process in the field. Thus sample size was determined by the level of information
saturation in each group (Table 1). Sampling was purposive and directed by the information
need. Three categories of informants (clients, staff and leaders) were identified and interviewed.
The selection was based on their primary role and willingness to participate in the study.
Table 1: Study population of selected health facilities in Addis Ababa, Ethiopia, 2009
Facilities SSIsClient*
SSIs
staff*
Key
informant
Observation of
consultation
Observation
of the health
facility
Zewditu
Referral Hospital
17 04 -- 04 01
Bole
Health Center
17 03 -- 03 01
Total 34 07 03 07 02
*The number of SSI client was not fixed, we continued to interview different ARV
clients till we reached a level of saturation of information.
4.6   Data Collection
A combination of data collection tools were used to gather the information in this study. Tools
used for data collection included semi-structured interviews (SSIs), observation of consultation,
health facility observation check lists and key informant interviews with identified community
members.
Data were collected by the principal researcher and his assistant/s. The assistants of the principal
researcher were ART trained BSc nurses. Prior to the start of the interview, a full day orientation
on the SSIs and on the methods of tape-recording and data scripting was given to the research
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assistants. The task of the assistants was to manipulate on tape-recording and to script the
verbatim. The research team had conducted semi structured interviews and key informant
interviews. Observation of consultation and observation of the facilities in both sites with notes
compiled on themes related to adherence were conducted by the principal researcher.
We used semi-structured, open-ended interview guides with flexible probing, with ART clients
and ART service providers. Thirty four SSIs with ART clients and seven SSIs with ART service
providers were conducted. In-depth interviews were conducted with key informants that are
playing leadership role to obtain personal experiences of ART from the subjective perspective of
each respondent. Three key informant in-depth interviews were conducted from Addis Ababa.
The aim was to establish: believes about HIV and ARVs, and the problems with adherence.
Observations of actual consultations were made in the study facilities using uniform observation
check lists. A total of seven observations of consultation with the staff (Doctor/Health Officer,
Nurse and Pharmacist/Druggist.); 04 in Zewditu hospital and the rest 03 in Bole health center.
The aim was to explore aspects, such as interaction between clients and service providers in
health facilities, the availability of ARVs stocks, stigma, and the length of time spent at the
facility, privacy and organizational procedures. Observational notes were taken and later used in
data analysis. The notes used to help fill in any gaps in the data obtained in SSIs and in-depth
interviews, and to triangulate data. Another method used for data collection was observation of
the health facilities.
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4.7 Data Quality
The following efforts were attempted to ensure the quality of data:
 Proper tape recording and hand writing /script/ of the interviews by the trained research
assistant,
 Intensive half day training to the research assistants about how to manipulate the tape
recorder and tape recording and how to take notes easily and fast during the interview,
and
 Verbatim transcription of all the data by the principal researcher.
4.8 Data Entry and Analysis
The interview was conducted in Amharic. After translating into English, the scripts become
ready for further data entry, analysis and write-up. Coding was done manually. Data were then
summarized under identified themes areas. We used framework analysis technique in finding
explanation by displaying/charting the full dataset: It enabled us to get easy access for revisiting
the synthesized data, allows us researching within cases across a range of different themes or
phenomena and allows us also moving from thematic and case based analysis
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4.9 Operational Definitions
1. Adherence to ART means taking the medicines in the right quantities and at the
right time
2. Antiretroviral (ARV) are medicines designed to suppress the replication of HIV and
prevent the progression to AIDS
3. Antiretroviral therapy (ART) is an HIV treatment involving the use of a triple
combination of ARVs
4. CD4 T-Cell is a blood test involving a CD4 cell count. It can be used to determine the
stage of the disease and is one of the criteria when to initiate ART.
5. Clients are people who use HIV treatment services available in the health facilities.
6. Double Contraceptive; Using two contraceptive methods (like contraceptive pills and
condom) at the same time
7. Tebel or Tsebel; is a ‘holy water’ believed to be a spiritual remedy
8. Teratogen; is an agent which may affect the embryo or fetus if taken during
pregnancy
9. Undetectable Viral Load is when the HIV is not detected by the Viral Load Machine.
10. Unprotected sex; Is a penetrative sex (insertion of the penis in the vagina or anus)
without using a condom
11. Viral load is a level of the virus found in the blood per 10 milliliters (mls)
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4.10 Ethical Considerations
Ethical clearance was obtained from University of Gondar. A formal permission for conducting
the research was obtained from Addis Ababa Health Bureau, Zewditu Hospital and Bole Health
Center following the administrative hierarchy. The following ethical considerations were
emphasized, addressed and dealt with properly.
 Individual informed consent was provided to every ART client who was interviewed with
all details attached on the annex.
 Confidentiality was protected; all the tape-recorded materials will be destroyed after I
defend my thesis.
 Privacy was kept to the maximum.
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5: Results
5.1: Demographic characteristics of ARV users
The study was conducted in Addis Ababa, which the capital city of the country. Two
health facilities had been selected one from the ART hospital, which is Zewditu hospital and the
other from ART health centers, which is Bole HC.
All of the study participants were 18 years of age and above; so the study excluded
pediatrics ART. The three key informants were leaders of well known HIV positives’
associations and were ARV users. A total of fifty one respondents (twenty five from Zewditu
hospital, twenty three from Bole HC and three key informants ) participated in the study by using
semi-structured and in-depth interviews and consultation observation of the ART providers.
Observation of the two health facilities also conducted using similar check list.
Demographics were calculated for all ARV users who participated in the semi-structured
interviews
Thirteen (38.24 %) of the ARV users interviewed were males and twenty one (61.76%)
were females. The lowest age for male study participants is 30 and the highest age for male
participants is 51; with a range of 21 and a mean age of 38.15.The lowest age for female study
participants is 22 and the highest age for female participants is 55; with a range of 33 and a mean
age of 34.90 (Table 2)
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Table 2: sex and age distribution of ARV users, Addis Ababa, Ethiopia, 2009
Sex Age in Years
Male
N=
Mean age = 38.15
Lowest  age = 30
Highest age = 51
Range = 21
Female
N=
Mean age =34.90
Lowest age = 22
Highest age = 55
Range = 33
Most of the participants from Zewditu hospital (47.06%) had been on ART for at least
three and half years; and most of the ARV users of Bole HC (29.41%) had been on ART for 3-6
months (Table 3). So, ARV users from Zewditu hospital had took for a longer period compared
to the Bole ARV users. Zewditu hospital is one of the first ART sites which have started ART
before four years. Health centers on the other hand, have started ART program within the last
two years after MOH has pledged decentralization of ART down to the health centers.
When we look the aggregate results; most of the participants (ARV users) from the two ART
facilities (32.35%) had been on ART for at least three and half years; (Table 3). Again, it should
be noted that some of the ARV users in Bole HC were those transferred from ART hospitals; that
is why 17.65% of the ARV users in Bole HC were those who took ARVs for at least three and
half years (Table 3).
Of 34 ARV users interviewed using SSIs, 14.71% had no education, 14.71% had
attended primary education, 61.76% attended secondary education and the rest 8.82 had attended
tertiary education (Table 4)
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Table 3: Length of time participants had been taking ARVs by site, 2009
Duration
taking ARVs
(months)
Zewditu Hospital Bole HC Total
Number Percent Number Percent Number Percent
3-6* 02 11.76 05 29.41 07 20.59
7-12 01 05.88 01 05.88 02 05.88
13-18 01 05.88 01 02.94
19-24 04 23.53 04 23.53 08 23.53
25-30
31-36 01 05.88 03 17.65 04 11.76
37-42 01 05.88 01 02.94
43+ 08 47.06 03 17.65 11 32.35
Total 17 99.99 17 100 34 99.99
*Those that had started ARVs within < 3 months are excluded from the study.
Table 4: Educational status of study participants, Addis Ababa, Ethiopia, 2009
Educational Level Number who attended Percent
No Education 05 14.71
Primary 05 14.71
Secondary 21 61.76
Tertiary 03 08.82
Total 34 100
About half of the ARV users from Zewditu hospital had to travel at least 11 Km to the
clinic to get their drugs. Health care providers from the two ART sites mentioned that longer
travel distance is one of the factors which adversely affects adherence (Table 5). Most of the
ARV users from Bole HC (88.24%) were coming from a distance of 10 Km or less. When we
observed the aggregate (ARV users from Bole and Zewditu ART sites); 70.59% were coming
from a distance of 10 Km or less. The ART service providers further mentioned that; shorter
travel distance improved adherence. Most of the ART service providers suggested that ART
service should be available to the nearest area where ARV users live. (Table 5)
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Table 5: Distance traveled to the health facility by ARV users on each visit, 2009
Distance
(KM)
Zewditu Hospital Bole HC Total
Number Percent Number Percent Number Percent
1-10 09 52.94 15 88.24 24 70.59
11-20 05 29.41 02 11.76 07 20.59
21-30 02 11.76 02 05.88
31-40
41-50
51+ 01 05.88 01 02.94
Total 17 99.99 17 100 34 100
5.2: Factors Influencing Adherence to ART
5.2.1: Costs and distance
Even though all of the ARV users interviewed were getting their medicines free of
charge, additional costs were incurred for transportation and for food. Cost incurred in general
affects adherence to ART. One ART service provider physician from Zewditu hospital said; cost
for food and transport has an implication on adherence…“Most of our clients are from the poor
society, they don’t have enough food to eat, and some of them are not able to afford transport
fees. These factors can adversely affect adherence” (Z-Ssi-Pro-02)
One HANS nurse from Zewditu hospital said that, those clients who are coming from far
area may face a problem in laboratory investigation…“There is no problem in the drug,
Probably on CD4, they have to come very early in the morning for the test; for some of our ART
clients it is too far for them” (Z-Ssi-Pro-01). One ART client also mentioned that she has to
travel long distance to get her ARVs…“I travel about 500 KMs in order to get my ARVs from
Zewditu hospital. I have to spend 400 birr for a round trip. I travel every three month; I will be
discriminated and stigmatized if I receive my ARVs in the place where I work” (Z-SSI- Cli-07)
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5.2.2: Food/Hunger
When ARV users become healthier after initiating ARVs most of them regain appetite.
Some patients interviewed from the two ART sites claimed having insufficient supply food to
match their rising appetite as they began to feel better. Lack of food found to be one of the
factors for poor adherence. An elderly poor lady from Zewditu hospital has told us a sad story
about the food problem she faced while she initiates ART...”When I started the ARVs; you fill a
dragging sensation after you swallow the pills; you need food. ‘Now the lady starts weeping’. My
appetite has improved markedly, but I didn’t have enough food to eat. ARVs make you very
hungry. I thought of discontinuing ARVS…but my kids have no one to support them: due to these
reasons I changed my mind and decided not to discontinue my ARVs.” (Z-Ssi-Cli-04)
Few others complain that they are engaged in heavy work but were not able to get
adequate food. One ART client from Bole health center has such a complaint: “My CD4 was
160 when I started ART, four years ago, now it is 216. I can carry 100 K.G of weight. I have very
good appetite but have no enough food to eat. I didn’t increase in body weight.” Further stated
that; “Shortage of food, hunger: it is usual. Besides, I have a lack of shelter; I have sheltered in
my supporters house” (Z-Ssi-Cli-16)
One of the ART service provider from Zewditu hospital said that, some of the ARV users
threatened to default ART and go to other places, like to tsebel if they face lack of food…
“Lack of food has a huge effect. In some places food is provided. Clients say that if the food is
discontinued they warn to go to other places.” (Z-Ssi-Pro-04)
In spite of the food shortage facing some ARV users, there were few attempts to alleviate
the problem. A lady key informant has described one of the attempts as follows: “For the needy
there is a food support program by FAO, through the association called Hiwot HIV. Previously
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the food support was given for longer period, but at present food support is given only for six
months assuming that these people will regain health within this period and become productive
again. By the Keble HIV desk, those capable ARV users are given skill training and provided
with seed money for IGA. I know people who under gone under this activity in my Keble” (Key
Informant-01)
5.2.3: Stigma, discrimination and disclosure
Stigma and discrimination towards HIV/AIDS had relatively improved as compared to
the past pre-ART era. The great contribution goes to the ‘provision of free ART.’ The
government and the people at large contributed a lot in reducing the stigma and discrimination
mainly by availing ART and HCT services in many parts of the country. While there is a relative
success in reducing the level of stigma and discrimination at the national level, these problems
exist at individual, family and community level. Most ARV users and all of the three key
informants who participated in the study mentioned that there is still stigma and discrimination
related to HIV/AIDS.
A 35 year male ARV user from Bole health center said that: “If some body is ill and bed
ridden secondary to AIDS, no one will visit him and give care and support. But if his/her illness
is other than AIDS, they visit the patient and provide care and support.” (B-Ssi-Cli-10)
A 32 year old lady from Bole HC claimed that she had been discriminated by her sisters:
“I was very much discriminated by my sisters when I was sick; they didn’t want to eat with me
and stopped to come to my room, they even didn’t want to touch my clothes: they think that, I
will not recover. But after I start ART, and when they observe the improvement, now we live in
peace. Only my female friend had helped me a lot while I was sick” (B-Ssi-Cli-01)
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A 26 years old lady from Zewditu hospital said that she had been stigmatized and
discriminated by her mother: “Specifically, my parents sadly discriminated me after I disclose
my HIV positive sero-status. My mother, probably she may not have awareness and Knowledge.
She sadly, discriminated me. After she become aware of my sero status, automatically she
dismissed me from home. At that time I was in dismay, I was in astray. Lord has helped me, now
I am in good condition. After leaving my home, I suffered a lot; I have no place to reside. Now I
am working and able to afford for living.” (Z-Ssi-Cli-01)
A 30 year uneducated male ARV user from Bole ART site said: “I disclosed my HIV
status to my wife and to all my neighbors. I have been stigmatized and discriminated by my
neighbors. In my case ‘I feel free’ by disclosing. Only children come to my house. My neighbors
even have stopped to come for coffee in my house and also they stopped inviting me for coffee in
their house” (B-Ssi-Cli-05)
Even though there is a relative improvement in disclosure of the HIV positive status;
many ARV users still didn’t disclose their HIV positive status to a none-family member fearing
the stigma and discrimination. A 35 year old lady from Zewditu hospital said that: “I didn’t face
any stigma and discrimination, because I didn’t disclose my HIV status to any one: I didn’t
disclose to any one because of what I saw in those who disclosed.” (Z-Ssi-Cli-02)
A 32 year old female client from Zewditu hospital complained that her best female friend
has discriminated her after disclosure: “I had an old female friend she always discriminate me
when I go to her home. I like her very much: she is the one whom I disclose my HIV positive
status for the first time, when I face the problem. She is giving me a drinking water with a
discarded cup, glass or other drinking utensil. Any way, I like her; I don’t want to depart her.
When she comes to my home, we will have coffee” (Z-Ssi-Cli-12).
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One lady ARV user from Bole HC told us that her former husband was taking ARVs
without disclosing his HIV status and ARV use…“I disclosed my HIV positive sero-status to my
sisters and my mother. My husband also knows. I was married, but divorced. My former husband
now lives in USA. We have a son he is living with his father in the states. My husband is also
HIV positive; I heard a rumor that he was taking ARVs secretly while he was in this country”
(B-Ssi-Cli-01)
Furthermore, many who have disclosed their HIV positive status, they disclosed only to
one or two of the family member or a friend. We encountered few ARV users who never
disclosed their HIV positive status to any one. The reason they mentioned for not disclosing their
HIV positive status was fear of stigma and discrimination. They claimed further that they didn’t
face any stigma and discrimination because they didn’t disclose their HIV positive status. Still
many of the ARV users who disclosed as well as not disclosed their HIV positive status were
taking their ARVs secretly. We had seen many of the ARV users throwing the drug box in to the
basket. The principal investigator found Efavirenaze full sealed box (of 30 tablets) in the basket
and handed over to the pharmacist. It was confirmed that it had been thrown unknowingly by one
male ARV user, thinking that he had thrown only the drug box.
A male key informant from Mekdem Ethiopia said that many ARV users are still taking
their ARVs secretly because of fear of stigma and discrimination…“ARV users are still taking
their ARVs secretly. Secretly from their families …some ARV users swallow the pills without any
liquid by hiding them selves from others. Even in their homes, ARV users are keeping ARVs in a
locked cabinet to hide from their families. But in contrary, there are some users who disclosed to
their families, so that the family members are supporting to take the ARVs properly. As the
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stigma and discrimination is improving, the disclosure to the family members has also
increased” (Key informant-01)
Few ARV users reported that they were abandoned by their spouses and their marriage
end up in divorce. A 34 year old male client from Zewditu hospital said that: “I was performing
heavy labor: I developed weight loss and generalized weakness. Especially my parents and my
family had insisted me for HIV testing; so I went to hospital for VCT. My wife and all my six
children where tested negative for HIV. (The youngest children are triplets of three years of
age). My wife has divorced me when I was tested HIV positive; she took with her three children
and I took also three children. My parents and my brother are fully supporting me and the three
children.” (Z-Ssi-Cli-15)
Some ART clients claimed that they had faced stigma and discrimination mainly at home
and in work places. A 35 year old lady from Bole health center claimed she was discriminated by
her relatives: “I had been discriminated and stigmatized when I was sick; I had only a small
lesion over the lip; they stigmatized me the moment they know my HIV positive status. At that
time I went to my sister’s house for care and support. They feared that they will get HIV from
me. I took care of my self.  I was washing my close and cleaning my room: I vomited once, no
one came for support; I have to clean the vomitus and every thing by my self. It is hard for the ill
person, like me. They were not eating and drinking with me; I was totally isolated. The drinking
cups and glasses and the eating dishes were also isolated not to be used by anyone else except
me. But now I didn’t face any stigma and discrimination by my relatives. We eat and drink to
gather. In the work place, even though my boss knows my status; I didn’t face any stigma and
discrimination” (B-Ssi-Cli-17),
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A 35 year old male ARV user said that he had been discriminated both by his relatives
and work mates: “Most of my work mates and friends and my relatives too has discriminated me.
Only my wife is on my side” (B-Ssi-Cli-10)
A male ARV user from Bole health center claimed that he has been discriminated from
the work place: “I disclosed for my wife, and also, I taught to 10 people, who are my work mate,
by disclosing my HIV status. Unfortunately, they discriminate me in the work place; they impose
a problem on me. Some times I observe when people are pointing at me, but I have seen these
people being HIV positive like me.” (B-Ssi-Cli-04)
Another lady from Bole health center, who had been infected with HIV after she married
to an HIV positive person, said that: “I faced a lot of stigma and discrimination: In the work
place, in my living area. This is because of my disclosure: HIV positives will remarry a negative
one when they divorce their wife or when their wives died. I am a victim of such event. I have
been also discriminated from the house I rent. They ordered me not to use the shared latrine. I
have been also repeatedly forced to leave the house I rent. It happens four times. My parents
have also discriminated me; they say that “she marries voluntarily without being tested for
HIV”. Still they are discriminating me. On the work place, our employers think that we are
unable to work: they think that our brain is not able to think. While we are able to perform
smartly: they think that we are unable to do everything, because we are positive. It is a mental
trauma; frustrating. We are able to perform the job nicely; but they assign HIV negatives in a
job which we can perform better” (B-Ssi-Cli-07)
A 47 year old ARV user from Bole clinic said he has not been discriminated in the work
place because he didn’t disclose his HIV status there: “My supporters and my relatives didn’t
discriminate me. In fact some people, still do not want to sit with me and to eat with me, some
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are pointing their finger on me; any way the stigma and discrimination is improved. I face no
problem in the work place. It is because no one knows my status” (B-Ssi-Cli-16)
One female key informant said that she knows many HIV positives that face a sever form
of stigma and discrimination when there was no ART in the country: “I know more than 100
peoples in Dawn of Hope who have been suffered a lot after disclosure. I know a mother who
damp her HIV positive son in the ‘dog cage’ and put the dog in the house. She was giving food to
the son ‘like a dog’. At that time there was no ART; they were not able to work; they had no
support and had no hope. I know a lot who died as a result of discrimination secondary to
disclosure.” (Key Informant-01)
Among the ARV users few are devoid of visa, especially to Arab countries because of
their HIV positive status. We heard from the ARV users that being HIV negative is still a
criterion to get a visa for work or live in Arab countries: A 32 year old lady from Zewditu
hospital claimed that: “I was in Beirut; my employer had made me tested for HIV without my
consent. They force me to be tested; I was not able to communicate in Arabic. She further stated
that; ‘I have been dismissed from work in Beirut because I was found to be HIV positive. I think
this is discrimination. Here in Ethiopia I face no discrimination; I disclose my self to the society
and also I am a member of Dawn of Hope.’ ” (Z-Ssi-Cli-10 l)
In the contrary, we encountered also some ARV users who claim gaining love, empathy,
tranquility, and support after disclosing their HIV positive status. A 55 year old lady from Bole
health center, who lost her husband by AIDS, expressed her feelings as: “My neighbors show
empathy for me. They say ‘don’t assign her to hard work’; they see me as if resurrected after
death. I don’t know whether they know my HIV status or not. They know that I am taking pills;
but I don’t know whether they know it is ARV or not” (B-Ssi-Cli-09)
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A male key informant from Mekdem Ethiopia said that: “Some people motivate AIDS
patients to initiate ART; at the other end there are peoples who insult and tease ARVs users; by
saying ‘chew (eat) your medicines’. People have realized that ART turned AIDS patients to be
productive, healthy and effective; the problem is, there is ‘self discrimination’, meaning that
AIDS patients fear to go to the health facilities and discriminate them selves. Stigma and
discrimination is seen more on those who have a fear.” (Key informant-01)
A key informant who is also a founder of a positive women association said that: “I
disclose my status to my mother 10 years after being positive for HIV. I delayed to disclose
myself, even to my mother, because of fear of the stigma and discrimination. But after my
disclosure to my mother, she said that ‘I would have helped a lot if you disclose to me earlier’”
(Key informant-01). A 31 year old, final year master’s program student from Zewditu hospital
said: “My HIV status is known by all of my family members. I face no stigma and discrimination
by my family. I gain rather acceptance” (Z-Ssi-Cli-06)
5.2.4: Care and support and disclosure
There are different care and support activities to the needy HIV positives, like food
support, financial support, IGA, home base care and so on by different organizations. One key
informant said that there is some form of care and support activities by different organizations
and associations: “For the needy there is a food support program by FAO, through the
association called Hiwot HIV. Previously the food support was given for longer period, but at
present food support is given only for six months assuming that these people will regain health
within this period and become productive again. By the Keble HIV desk, those capable users are
given skill training and provided with seed money for IGA. I know people who under gone under
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this activity in my Keble. We provide health education; There are different HIV positives’
association like; Dawn of Hope, Mekdem Ethiopia, ‘My Sisters’ and so on, which are engaged in
teaching people by modeling them selves (HIV positive status). There is also home based care
service (HBC). ‘Hiwot HIV’ association is providing HBC in sub cities of Kirkos and Nefas Selk
Lafto sub cities. There are about 5 HBC providers in each Kebles; HBC is being provided in 10
Kebles. It means there are about 50 volunteers (both HIV positives and negatives), who provide
the HBC service in these two sub cities. (Key informant-01) Many mentioned that receiving
adequate care and support from families, friends and organizations will enable ARV users to
adhere more to the treatment regimens.
5.2.5: Drug regimen and side effects
To attain a marked reduction in the occurrence viral resistance and to achieve viral
suppression to the level of undetectable viral load, combined treatment with at least three ARVs
is needed. This is commonly called HAART (Highly Active Anti-retroviral Therapy) in the
western world, and ART (Anti-retroviral Therapy) in most of the African countries. SSI is
conducted to 34 ARV users with probing, in the two ART sites; none of them were in the 2nd line
ARVs. The type of regimen is known to affect adherence to treatment. The following section
tries to summarize findings that are related this issue.
All of the ART service providers witnessed that; even though there is irregular shortage
of some of the drugs for OIs, shortage of ARs were never seen in their facilities. Most of the
clients were taking 2-3 ARVs in the morning and 2-3 ARVs at night. But, since the last six-eight
months most of the clients interviewed confirmed that the drug regimen is shifted to a ‘fixed
dose drug regimen’, meaning that they are taking a pill with three ARVs in it; one pill in the
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morning and another pill at night; again most of the clients expressed their satisfaction with the
new fixed dose ARVs regimen, by stating that it is easier to take so that it contributes to adhere
better compared to the previous ARVs regimen. A 32 year old female from Bole health center
said that: “Initially I was taking 3 tabs in the morning and 3 tabs at the evening. Since 8 months,
I am taking one tablet in the morning and one tab in the evening. This is because the drug is
changed to a fixed dose regimen.” (B-Ssi-Cli-013) A 26 year old female from Zewditu hospital
confirmed that: “I was taking four drugs per day, now I am taking a drug which is taken twice a
day” (Z-Ssi-Cli-01)
Few ARV users claimed to have experienced side effects just after the start of ARVs; all
were transient and relieved with out any treatment or with symptomatic drugs. Some of the
ARV users, especially from Zewditu hospital developed chronic side effects due to stavudine
(d4T). They become disfigured due to lipodystrophy effect of d4T. In all those who developed
this chronic side effect stavudine is changed to TDF or to zidovidine (ZDV, AZT), after
performing appropriate laboratory investigations. A 32 year old female from Zewditu hospital
said that: “My ARVs drug regimen is changed twice; initially a drug called Stavudine has
disfigured me by developing a big abdomen, thin limbs and a depression over the cheeks and
thinning of the face. So Stavudine is changed to TDF about six months ago. Recently, nevirapine
is changed to efavirenaze, because I develop hepatitis” (Z-Ssi-Cli-10)
Other commonly seen side effect next to the side effects of stavudine is the side effects
related to nevirapine; like rash, burning and numbness on the extremities. A 34 year old male
from Zewditu hospital said that: “My ARVs were changed once because the ARVs caused
burning and numbness on my legs and feet” ((Z-Ssi-Cli-15)
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Some side effects were related to wrongly ordered ARVs which are contraindicated to the
specific ARV user. One ARV user had developed epileptic fits after the start of efavirenaze
containing ARVs regimen. He claimed that he had single epileptic attack years ago. At present
he is getting phenitoin with efavirenaze containing regimen. One efavirenaze containing ARVs
user lady said that; she was taking this regimen while she was pregnant. It is known that
efavirenaze may have a teratogenic effect if taken during pregnancy, especially during the 1st
trimester. Any lady in a reproductive age taking efavirenaze containing ARVs should strictly use
double contraceptive; or efavirenaze should be changed by other ARV, like, nevirapine after
LFT, if she has a plan to conceive. It shows that there is a problem in counseling the ART
clients.
Few ARV users delayed initiating ARVs due to fear of side effects. A female informant
from Zewditu hospital stated that: “Regarding the side effects, even once I decided not to take
the ARVs because of the things I heard about the ARVs side effects. I delayed to decide in taking
ARVs for five to six months because of fear of side effects and adverse out comes. But after I start
the medication, I become healthy and face no problem.” (Z-Ssi-Cli-01)
Other reasons for changing or defaulting ARVs include lack of weight gain, pregnancy
and being fed-up of taking ARVs. A male informant from Zewditu hospital confirmed that:
“After taking the ARVs for the first six months, it is changed to other ARVs because of no gain of
body weight and increment of the CD4 count” (Z-Ssi-Cli-06) A female informant from Bole
health center said that: “When I initiate my ARVs in Black Lion hospital, I developed loss of
appetite, nausea and discomfort: so my ARVs were changed a month after the start of my ART”
(B-Ssi-Cli-08)
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None of the ARV users interviewed had discontinued their ARV as a result of the side
effects. However, one of the key informants said: “Some people become boredom of taking ARVs
and become a defaulter. I know five cases who defaulted claiming that they are tired of using
ARVs. After we teach them that they shouldn’t default, all of them resume ART” (Key informant-
01)
5.2.6: Other Reasons for Missing and/or delaying ARV doses
Delaying in taking the ARVs on time was a problem faced by many ARV users from
both ART sites. Also some of the clients had confirmed that they missed a dose of ARVs at least
once after they start ART. The common reasons mentioned for delaying or missing the ARV
dose were: work, travel, tebel, fasting, sleep, lack of disclosure, forgetfulness, lack of disclosure,
health conditions, time of class attendance, lack of electric power and so on. A 42 year old lady
from Zewditu hospital said that: “I will travel to provinces for field work, as a result of long stay
the drug might be over before I return to my home. I face such problem only once, since then I
always hold more drugs when ever I travel. The interruption was only for a day, even in that
day; I was able to return and took the night dose. Or else, I will discontinue my field work and
return to my home town if there is any shortage of ARVs” (Z-Ssi-Cli-02)
A 22 year old lady from Zewditu hospital said: “I usually forget taking the drugs with me
when I go to other places, to pass the night there. At night also I may sleep, the time passes when
I wake up. Two days ago, I took my ARVs at 11 PM at night, but it should be taken at 9 PM. It
happens because I slept.” (Z-Ssi-Cli-05)
A 42 year old male ARV user from Zewditu hospital stated that: “I forget when I am
angry in the work place. I am an expert patient; if you forget taking ARVs you can take it within
4 hours otherwise you have to take it together with the next dose. Also when I am in a hotel with
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friends I afraid to take the pills freely, this is because of fear of stigma and discrimination” (Z-
Ssi-Cli-08)
A 32 year old male from Bole HC said that: “I missed a dose for about 10 occasions.
This is because, when I go to a field for work (I am a driver), I may not return to home to take
the next dose I discontinued once also for two months because I am working in power station
project” (B-Ssi-Cli-14)
A 31 year old male masters’ program student from Zewditu hospital stated: “Sometimes I
forget my drugs, probably it may be due to lack of convenient or suitable time to take the pills.
Meaning, some times I will take the drugs with me. But I forget to take it when I am in class
(school). It happens because I may be impressed by the learning session or the environment may
not be conducive to take my drugs freely.” (Z-Ssi-Cli-06)
A 41 year old male from Zewditu hospital said that: “I missed taking my ARVs twice,
because my mobile had no power. I use mobile alarm to remind me” (Z-Ssi-Cli-09) A 35 year
old female from Bole HC: “I have been delayed in average about one hour. This happens when
there is no electric power; so I am not able use a radio to remind me the time, because it needs
electric power. These delays had occurred about 20 times since I start my ARVs. I have neither a
watch nor a clock” ” (B-Ssi-Cli-17)
A 35 year old lady from Zewditu hospital said that: “When the place is not suitable I will
not take my ARVs; my parents do not know that I am taking ARVs, so usually I delay in taking
my ARVs. This happens when they come to my house or when I go to theirs’. I always go with my
drugs, only the pills I need from the bottle, but not suitable to take it, so I delay. When I delay I
will not take that dose, I will take only the next round dose.” (Z-Ssi-Cli-11)
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A 55 year old female from Bole HC said: “I sometimes delay in taking for about ½ to 1
hour. In the time of “Siga wee demu”, Holy Communion, I will not take my morning dose,
because I am fasting at this occasion. It happens once in every 40th day. It is a belief among
Orthodox Christians.” (B-Ssi-Cli-09)
A key informant explained the issue of fasting as: “The issue of fasting among the ARV
users is an area which is not addressed in targeting adherence. Still people miss or delay in
taking their ARVs due to fasting. But the church claims that those who are weak are not obliged
to fast; they can praise their lord with other means of pray act. Religion further state that ‘those
who insist fasting can take only their pills with plane clean water’. This issue should be
addressed and included also in the ARVs adherence package and the religious leaders should
preach also about this issue.”(Key informant-02)
5.2.7: Traditional medicines, beliefs and misconceptions
Another set of factors affecting adherence included traditional medicine and other
traditional/cultural beliefs and common misconceptions. Tebel, which is considered to be a’ holy
water’ was taken by many ARV users. Many of them who took tebel they took their ARVs also
regularly and on time together with the tebel. Few ARV users stopped their ARV for months by
going to tebel area.
Few other ARV users said that they stopped tebel when they started ART; because tebel
didn’t bring any improvement on them. A 35 year old female from Zewditu hospital said that: “I
am drinking tebel always; I am taking it even before I was ill. I am drinking about a liter of tebel
daily except in the period of menstruation.” (Z-Ssi-Cli-03) A male informant from Bole HC
stressed that: “Tebel is a must. I believe in it as a Christian. I am taking a liter in empty stomach
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in the morning. I am taking tebel for about 13 days per month. I am taking my pills with tebel”
(B-Ssi-Cli-15)
Few ARV users said that they took herbal medicine provided by the ‘local healers’ and
happen to interrupt taking their ARV. A 22 year old female from Zewditu hospital stated that:
“Two month ago I took herbal medicines; it looks like, ‘Gesho’, (Vernonia Amygdalina) dried
and crushed leaves. I took it orally for three consecutive days as instructed by the traditional
healer. Since I had a weeding ceremony, I interrupted taking this herbal medicine and after a
while I took it for additional two days. I discontinue taking it when I left with a day dose. After
this medication, I develop abdominal swelling (distension?), anxiety and generalized weakness. I
didn’t discontinue taking ARVs while I was taking this herbal medicine. But I didn’t take my
ARVs with the exact time. It happens because I want to take the two drugs (ARVs and the herbal
medicine) at different time, just to have a gap” (Z-Ssi-Cli-05)
Few ARV users also went to the ‘spiritual healers’ who claimed to cure HIV/AIDS by
praying and by their spiritual power. A 34 year old male from Zewditu hospital stated that: “I
heard that HIV is a satin. I, my self gone to a priest, who claims to cure HIV: I traveled there
regularly (daily?) for a month; but I was taking my ARVs as usual also. The priest associates
HIV with Gin. When the Gin leaves the victim (AIDS patient) by the priest’s spiritual power: the
priest claim that the patient becomes free of HIV: He preaches many extra ordinary things as if
performing many miracles. People pay money ‘Asrat bekurat’ (tithe or tithe by will) for him. He
becomes very rich, has 2-3 station wagons. The paper with his address is attached.” (Z-Ssi-Cli-15)
37
5.2.9: Structural/ health facility issues, quality of care and opinions of ART service
providers
Both of the health facilities had been observed with the same check list and both the ARV
users and the ART staffs had been interviewed about the structural/health facility issues.
Zewditu ART Site
The ART and VCT sites were clean, but there was only one toilet at the VCT site, the
ART site had no toilet. Currently the toilet is not functional. The ART clients were received in
the front corridor, veranda. They will get their card by inquiring through a small window. No
privacy at all, people from out side can identify any client from a distance.
In the VCT site privacy was well protected. There was a very neat waiting room with a
large screen television. This big room was also partitioned for a reception and card room. It was
comfortable and well designed to keep privacy. There were physicians, health officers, nurses,
pharmacy staff, laboratory staff and others like adherence supporters/case managers in the ART
site.
The health workers in general were highly dedicated to their work; respected and treated
their clients in a friendly manner. They showed empathy to the clients. The health providers were
working hard. They were starting work early before the working hours and late after the working
hours
In the ARVs dispensary area, the privacy was not well protected; it was open with the corridor.
Adherence counseling was done by ART adherence counselor in the main ART block. No
adherence counseling and no pill count were conducted in the ART pharmacy
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Bole ART site
There were five small pit latrines adjacent to each other in a circular area. Three of the
toilets were for males and the rest were for females. The latrines were not clean and there was
water around. The surface area of the latrine was spoiled with urine and dirt. Water was not spill
over the surface of the latrine. There was also one toilet for the ART health staff, but it was not
functional, because the sink was broken. In general the ART site and the HC were relatively
clean. The waiting area was in the veranda open at the in front. Patients were waiting in this area
till they are called to enter; there was privacy in each service room and clients were treated with
respect. There were health officers, nurses, pharmacy staff, laboratory staff and others like
adherence supporters/case managers in the ART site but there was no physician in this ART site.
The health workers in general were receptive. Treated their clients with patience and gave
a chance for clients to ask questions. There were reading posters posted over the wall and there
were also reading materials like fliers to provide for the clients. For those who initiate ARVs,
adherence counseling was also provided in the Pharmacy room. For the re-fills only a simple
instruction about the dose and timing of the ARVs were provided.
In both ART sites there was patient/client overload. In comparing the two sites; the work
load was seen more in Zewditu hospital. A physician from Zewditu hospital had described the
problem as: “There is high work load, and there is also attrition of the staff.” (Z-Ssi-Pro-02)
In Bole ART site there was no CD4 and chemistry machines. Patients were sent to
regional laboratory for CD4 and chemistry investigations and the results would be available 10
days later. The staff said that this is one barrier to adherence. An HO from Bole HC described
the situation as: “Most of the lab investigations are good; but there is a problem related to CD4.
The blood sample is collected in this ART site but the CD4 lab investigation is done in other
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place, in the regional lab; it is done only once in a week, the regional lab people collect the
blood and the result is available after a week, it may take even longer 10 days or so. The CD4
result is unreliable; some times, the patient is very ill but a high CD4 count is reported. Error in
writing the exact the number and displacing names are the other problems we face.
Thirty six ARV users involved in the semi-structured interviews were asked to comment
on the quality of services provided in the ART sites in terms of: trusting the health workers;
privacy during counseling; respect from health workers; whether the health workers listened to
the ARV users: and the general environment. Generally, many of the ARV users from both ART
sites were satisfied with the quality service they provided with. A 31 year old male from Zewditu
hospital has expressed his satisfaction like this: “The advice of the physician is very good; it helps
us more than the ARVs do.” (B-Ssi-Cli-16) Another woman from Bole said: “I’m treated very well;
I lack words to express my appreciation. Once I had a thought of killing my self, to hang my self;
they counsel me for hours. They enable me to stay alive and healthy. Thanks to God” (B-Ssi-Cli-
05)
On the issues of waiting time, many of clients in the two facilities were waiting only for
half an hour or less. Absence of pill count was the limitation observed in both facilities. Pill
count was done only two weeks after the initiation of ARVs. The ART service providers gave
their opinions about the level of adherence of their clients in relation to sex/gender, age, duration
of ARVs use, educational status and distance traveled. Many of the ART providers said that;
adherence was better among; males, elderly, those who took ARVs for a longer period of time
and those who had high level of education. Almost all of the ART service providers said that
those who were coming from far distance adhere less. They further stated that long distance is
one of the major challenges to ART adherence.
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The ART service providers further stated some use full recommendations in order to
improve the quality of the service: Many of them suggested; further training and advanced
education, incentives and availing means of transportation.
ART service provider from Zewditu hospital forwarded her recommendation as: “There
is a need for support; because the service causes ‘Burnout Syndrome’; there is a high work load,
we will exhaust due to the high work load, and there are many things which affect us
psychologically. Even a simple acknowledgment is better. Even you will be exposed to infections
like TB; in our facility we will give services to more than 200 clients daily. We come to the
hospital at 7 AM and leave the hospital in the evening; no one pays us the over-time, no
incentive. We never ask payment for over-time service but we will be happy if we got payment for
it. We continue working in this condition only because we got mental satisfaction when we see
severely sick patients get improved. But if there are incentives the attrition will be low: there is
no ‘Burn- out’ management; in other countries there is burn –out management to ART service
providers, we will be happy if it is provided also to us”… “I wish, at least if we get
acknowledgment for what we are doing… we observe people getting a prize for their good work;
in the health sector there is no such trend. I wish to see at least one health professional get such
a prize.” (Z-Ssi-Pro-02)
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6: Discussions
Fifty one participants including ARV users and health workers from the two ART sites
and three key informants from Addis Ababa were enrolled in this study and interviewed and/or
observed using one of the instruments designed to collect data. Besides, two observations of the
facilities were done based on the same check list. This study lays the ground work for future
quantitative studies and serves as a spring board for future subsequent quantitative/qualitative
studies as well as informing future interventions to tackle barriers of ART adherence and
improving adherence.
All ARVs and OI drugs are free. All 1st line ARVs recommended in the national
guidelines are available in both ART sites. Zewditu hospital has also free 2nd line ARVs. Health
centers are entitled to provide free 1st line ARVs only. For this reason Bole HC was providing for
the ART clients only 1st line ARVs and drugs for OIs. 2nd line ARVs were not available in this
HC. Regarding drugs for OIs, still there was a shortage of some of the drugs for OIs. In fact this
was one of the main limitations we observed in delivering quality ART service.
Costs for transport, for food while in ART site and other overhead costs were considered
to influence adherence: Some of the ARV users and many of the ART service providers
interviewed mentioned cost for transport is a challenge to ART adherence. Not only that, few
ART service providers mentioned that, some times, lack of means of transport is a problem.
This is a serious problem that is likely to affect adherence, even for those who try to be adherent
(03, 19, 33). If users fail to achieve optimal adherence; they may develop resistance to first –line
ARVs early.
The rapidly increasing food prices had affected the ARV users by large. With stagnant or
lowering income, the magnitude of the problem is becoming tremendous. Some organizations
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like FAO and other non governmental organizations and associations were providing food for
few ARV users who were poor and who had no supporters. They provided this service usually
for the first 6th months after the start of ART. One of the key informants had suggested that food
support for only the first six month is not enough. Hungry people are inclined to stop ARVs
because they can not afford to feed them selves as their body metabolism improves and the
demand for food increases. The ART program will face a series challenges unless the
government addresses the problem of low-income or no income ARV users. Since adherence is a
master key for the success of ART program: (8, 9, 10, 33) food support to the needy ARV user
should be provided till they become productive and able to generate money.
Even though the stigma and discrimination had improved compared to the past;
especially from the pre-ART era; the problem still exists in our society. Many of the ARV users
interviewed at both ART sites said; stigma and discrimination are still a problem, especially at
the micro level. Some had experienced stigma and discrimination within their immediate
families. Even few of the ARV users are forced to leave their home after disclosure. Few ARV
users have been abandoned or divorced by their spouse because of their HIV positive status.
There was still a stigma and discrimination in the work place. Some of the ARV users were
taking their ARVs secretly because of fear of stigma and discrimination. Even some of the ARV
users delayed or missed their ARV dose if there was some one around. Even though many of the
ARV users have disclosed their HIV sero-positive status and their ARV use; few clients never
disclosed their HIV sero-positive status and their ARV use to any one, because of fear of stigma
and discrimination: If ARV users do not disclose it is hard to get a support from others; they miss
or delay in taking their ARVs more frequently compared to those who disclosed their ARV use
(20, 21).
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While social, financial and food support is seen as a motivating factors for adherence,
lack of such support can have a negative effect on adherence (20, 21, 33). Few ARV users
acknowledged the food support they get from Keble and many others acknowledged the support
they received from their immediate families or friends. In particular, some stressed the
importance of support they get from their immediate family members to ensure they took their
medicine at the right time. Some associations and organizations, like Mekdem Ethiopia are
providing care and support to some of the ARV users who are poor. We have seen that Mekdem
Ethiopia is engaged in home base care (HBC), in financial and food support and in different
income generating activities (IGA).
For ART to achieve viral suppression, combined treatment with at least three ARVs is
needed. Some ARV users experienced different side effects just after the start of ARVs. Many
of them notified that, the side effects disappeared without changing the ARVs. Still some ARV
users experienced side effects after a longer use of ARVs. Most of such ARV users complained
of disfigurement of their body after a prolonged use of stavudine (d4T) containing ARVs. They
claimed that they had developed big belly, thin extremities and depression over the cheeks. All
of the ARV users who developed this complication confirmed that their ARVs were changed.
Usually d4T is changed to ZDV or TDF.
Even though the use of traditional medicines by HIV positives has been decreased after
availing free ART by the government and partners; still some HIV positives were seeking
traditional medicines. The most widely used was tebel, which is widely used by Orthodox
Christian ARV users. Previously, many ARV users were defaulting and go to tebel. In fact many
died there too.
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After the religious leaders advised the ARV users to take the ARVs with tebel, the condition has
improved a lot.
Lack of privacy; high work load and shortage of physician are serious challenges to
quality of services. Waiting time was short in the study facilities and did not hamper adherence.
All the ART service providers were strictly following the national ART guidelines. In both
facilities, clients were well respected and there was privacy during consultations. This motivates
and encourages clients to interact with the service provider freely. In both facilities pill count was
done only two weeks after the start of ARVs. Pill count is one of the tools for monitoring
adherence. This was one of the main limitations observed in the facilities (15, 33). In bole ART
site there was no CD4 and chemistry machine. Clients were sent to regional laboratory and
results will be available after ten days. This is one of the barriers for adherence because patients
may seek other options in the mean time.
Strength of the Study
The data are collected from two health facilities in Addis Ababa. Zewditu hospital has a
lot of ART clients compared to other ART sites in Addis Ababa. It has more than 5000 ART
clients and Bole HC has more than 1000 clients; moreover, Zewditu hospital is one of the first
ART hospitals and Bole health center is also among the first ART health centers in this country.
So it was easier to find clients who took ARVs for a longer period of time.
By directly quoting statements from study participants and by direct observations we are able to
generate plenty of information. The qualitative data provide in-depth inside into peoples’
experiences and challenges with ARVs.
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Limitations
Data collection and transcription consumed much of the available time for the research.
So very little time was left for analysis and writing the paper. There are also other limitations of
the study. For example, some of the data collection methods used in this study relied on self-
reports of adherence behavior, which is prone to response biases. In addition, we used client
samples that were currently on ART and did not include individuals who had discontinued
treatment. It is possible that those with poor adherence may no longer be visiting the treatment
facilities. The other limitation of the study is, it doesn’t include pediatrics ART users. We were
not able to include pediatrics ARV users because of the very limited time allocated for the
research. So it will be difficult to understand the holistic challenges of adherence.
Generalizability/Transferability
We selected Zewditu hospital and Bole health center because these two ART sites have a
relatively more ART clients in comparison to the other ART hospitals and health centers in
Addis. Even though the result of the study can be generalizable to ART sites in Addis Ababa; it
is hardly possible to generalize the result of the study to other ART sites.
46
7: Conclusions
 The costs involved in terms of transport and other overhead costs are some of the existing
problems which affects adherence.
 Hunger/lack of food is usually a major concern, especially for the poor ARV users who
have just started ARVs. ART clients, key informants and ART service providers; all
reported that food shortage is a serious problem.
 Stigma and discrimination is among the major barriers to strict adherence. Some ARV
users never disclosed their status to any one; so they don’t have adherence supporters.
Still many of the ARV users are taking their drugs secretly. They may miss or delay in
taking their ARV dose in fear of not to be seen by others.
 The use of alternative therapy including traditional healers is causes of non-adherence.
 Lack of privacy at some service points such as pharmacy and unavailability of lab
services such as CD4 count are serious concerns to proper ART.
 Adherence monitoring using pill count is not strictly implemented.
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8: Recommendations
 Food support programs and other care and support programs have to be re-designed again
and food support and other care and support programs to the needy ARV users has to be
coordinated, integrated, monitored and sustainable. The government with the support of
the relevant stakeholders has to take a lead role.
 There has to be optimal privacy both in the consultation and pharmacy rooms. Pill count
during the date of appointment has to be conducted for every ARV user.
 Efforts to minimize constraints and improve adherence levels will require the efforts of
the community, health workers and clients as well as government commitment to resolve
key problems such as stigma and discrimination.
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10. Annexes
Annex 1 – Individual Consent Form
How are you Dear?
My name is Esmael Wabela Saleya, I am a medical doctor.
At present I am attending an MPH program, which is jointly delivered by Addis
Continental Institute of Public Health and University of Gondar
Besides, I am currently conducting a research on ‘Assessment of factors that affect adherence to
antiretroviral therapy among adults in Addis Ababa:’
You have been chosen to participate in this study by convenience. We hope you will help by
responding to the interview.
None of your answer will be available to any one.
Do not give your name. We really need your honest response to better understand the problems
associated with adherence to ART.
You have the right to stop the interview at any time, or to skip any question that you do not want
to answer.
The result of the study will hopefully serve as an important input to intervention programs that
target for optimal adherence.
We thank you in advance for taking your time to participate in the interview.
Would you be willing to participate in the study?
Agree____________
Disagree___________
Interviewer name, ________________________, Signature, ___________, Date_______
Supervisor’s name, _______________________, Signature, ___________, Date_______
*The Amharic version is attached on the next page.
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የተሳትፎ የስምምነትመግለጫ ቅጽ
ጤና ይስጥልኝ
ስሜ ኢስማኤል ዋበላ ሣሊያ ይባላል፡፡ የሕክምና ዶክተር ስሆን በአሁኑ ጊዜ አዲስ ኮንቲነታል
የፐብሊክ ሔልዝ ኢንስቲትዩትና የጎንደር ዩኒቨርሲቲ በመቀናጀት የሚሰጡትን የMPH ፕሮግራም
በመከታተል ላይ እገኛለሁ፡፡ በተጓዳኝም በአ.አ በፀረ ኤች አይ ቪ መድሃኒት ቁርኝት /Adherence/
አንፃር ባሉት ችግሮች ላይ ጥናት ጀምሬለሁ፡፡ ለዚህም የጥናት ተግባር እርስዎ ተመርጠዋል፡፡
ለምናደርግሎት ቃለ መጠየቅ እንደምትተባበሩኝ ተስፋ አደርጋለሁ፡፡ የሚሰጡን መልስና
መረጃ ከእኛ ውጭ ለማንም እንደማይገለፅ ላረጋግጥልዎ እወዳለሁ፡፡ ስምዎንም ለኛ መግለፅ
አያስፈልጎትም፡፡ ከርስዎ የምንፈልገው ትክክለኛና እውነተኛ መልስ ብቻ ነው፡፡ ይህም በፀረ ኤች አይ
ቪ ቁርኝት ዙሪያ ያለውን ችግር በጥልቀት እንድንረዳና መፍትሄውንም እንድናፈላልግ ይረዳናል፡፡
ሆኖም መጠይቁን የማቋረጥ ወይም ለመመለስ የማይፈልጉትን ጥያቄ የመዝለል ሙሉ መብት
አለዎት፡፡
በመጀመሪያ ለቃለመጠይቁ ተባባሪ በመሆንዎ ልናመሰግንዎ እንወዳለን፡፡
ፈቃደኝነትዎን ቢገልፁልን?
ተስማምቻለሁ
አልተስማማሁም
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Annex 2 – Information Sheet/Consent Form
(የጥናትማብራሪያና የተሳትፎ የስምምነትመግለጫ ቅጽ)
Information Sheet and Consent Form
Title of research project: Assessment of factors that affect adherence to antiretroviral
therapy among adults in Addis Ababa:
Site of the research- Zewditu Hospital and Bole Health Center
Principal Investigator: Esmael Wabela (M.D.)
Name of the Organization: University of Gondar and Addis Continental Institute of Public
Health
Sponsor: ________________
Introduction
This information sheet explains the research study that your organization/bureau is asked to
participate by allowing ART clients (under consent) and the health staff in the facility in order to
involve in the study, and giving an official permission for the study, including permission for
conducting a general observation of the health facility. Please review this form carefully and ask
any question about the study before you agree to join the study by giving the permission.
Purpose of the research project
 The objective of this study is to identify structural and patient-related factors to ART
adherence.
 Assesses the quality of the process involved in providing ART services for patients
attending the selected sites.
Procedures
Zewditu hospital and Bole health center are opted for the study and ART clients and the ART
staff of the hospital will involve in the study.
Risks / Discomforts
There are no risks out of the study to the health facility, health bureau and the health staff and
ART clients who involve in the study.
Anticipated benefits/Outcome)
The study will address:
 Possible factors (structural and patient-related factors) affecting adherence.
 Possible operational barriers to ART adherence.
 Possible interventions to be undertaken to improve ART adherence
54
Alternatives to procedures or treatments
The health facilities have the right not to participate in this study.
Sharing of new findings
The investigator will analyze the data and will provide one copy of the findings to the each of the
health facility and one copy to the health bureau.
Confidentiality
The information accessed through SSIs, observation of consultation, health facility observation
and key informant interview will not be displayed to anybody. After the study is over the data
extracted will be kept in a locked cabinet with Dr. Esmael Wabela for five years and then will be
shredded and disposed. The tape-recorded data will be deleted after I defend my thesis. Only
people who run this study will have access for the information.
Payments for participating
None
Voluntariness
The health facility is not obliged to participate in this study and have the right to prohibit the
interview and the observations.
Person to contact
If you want to talk to some one about the study you can contact Dr. Esmael Wabela, the principal
investigator of the study whose phone number is 0911 648219. Also you can talk to Professor
Yemanh Berhan, the advisor for this research. His phone number is 0911 219785.
If you have read this document and you have been given a chance to ask any question now or at a
later time and you agreed to make the health facilities to be in this study, please sign below.
Name ________________________
Position _______________________
Organization ___________________
Date _________________________
*The Amharic version is attached on the next page.
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የጥናትማብራሪያና የተሳትፎ የስምምነትመግለጫ ቅፅ
የጥናቱ ርዕስ፡- በአ.አ በፀረ ኤች አይ ቪ መድሃኒት ቁርኝት /Adherence/ አንፃር ባሉት ችግሮች ላይ
ጥናት ፡፡
የጥናቱ ቦታ፡ ዘውዲቱሆስፒታል እና ቦሌጤና ጣቢያ
ዋና ተመራማሪ፡ ዶ/ር ኢስማኤል ዋበላ
የድርጅቱ ስም፡ ጎንደር ዩኒቨርስቲ እና አዲስ ኮንቲኔንታል ፐብሊክ ህልዝ ኢንስቲትዩት
ስፖንሰር፡…………………………..
መግቢያ
ይህ የጥናት ማብራሪያ የሚገልፀው ድርጅትዎ ወይም ቢሮዎ በተዘጋጁት ቃለ መጠይቆች ዙሪያ
ከኤ.አር.ቲ ተጠቃሚዎችና ከጤና ተቋሞቹ ሰራተኞች ጋር ቃለ ምልልሱን እንድናካሂድና የአሰራሩን
ነባራዊ ሁኔታና የጤና ተቋሞቹን ነባራዊ ገፅታ እንድንዳስስ ቢሮዎ ፍቃድ በመስጠት የዚህ ጥናት
ተሳታፊ እንዲሆኑ ለማድረግ ነው፡፡
የጥናቱ ዓላማ
1. ለኤች አይ ቪ መድሃኒት ቁርኝት / Adherence/ ምክንያት ሊሆኑ የሚችሉ ተቓሚያዊ እና
ሌሎችምክንያቶች ለመለየት፡፡
2. የART ግልጋሎትን የጥራትመጠን ለመገምገም
የጥናቱ የአስራር ሂደት
ዘውዲቱሆስፒታል እና ቦሌ ጤና ጣቢያ ለጥናቱ የተመረጡሲሆን የጤና ተቓማቱ የፀረ ኤች አይ ቪ
ተጠቃሚዎችና የሆስፒታሉ የኤ አር ቲ ሰራተኞች የጥናቱ ተሳታፊዎች ይሆናሉ፡፡
ሊከሰቱ የሚችሉ ስጋቶችና የምቾትመጓደሎች
መረጃውን ለዚህ ጥናት በማዋል የሚከሰት ምንም ዓይነት ጉዳት በጤና ተቓማቱ እና በጤና ቢሮው
ወይንም በበሽተኛው ላይ አይከሰትም፡፡
ሊገኙ የሚችሉጠቀሜታዎች
1. የኤ አር ቲ ቁርኝት ላይ ተፅዕኖ ሊኖራቸው የሚችሉትን ተቋማዊ፣ እና ሌሎች ምክንያቶችን
ለይቶማውጣት
2. ለኤ አር ቲ ቁርኝት እንቅፋት ሊሆኑ የሚችሉምክንያቶችንመለየት
3. የኤ አር ቲ ቁርኝት እንዲሻሻል ሊወሰዱ የሚገባቸውን እርምጃዎችማመላከት
የአሰራርሒደት ወይምሕክምና አማራጮች
የጤና ተቓማቱ በጥናቱ አለመሳተፍ ከፈለጉ አለመሳተፍ ይችላሉ፡፡
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የጥናትውጤቱን ስለማካፈል
ጥናቱን ዋና ተማራማሪው አጠናቅሮ ከጨረሰ በኋላ ለጤና ተቓማቱ እና ለጤና ቢሮው አንድ አንድ
ኮፒ ይሰጣል፡፡
ሚስጢርመጠበቅ
የግለሰቦች መረጃ ለማንም አይገለጽም፡፡ ጥናቱ ከተጠናቀቀ በኋላ የተሰበሰበው መረጃ በሚቆለፍ ሳጥን
ውስጥ ከዶ/ር ኢስማኤል ዋበላ ጋር የሚቀመጥ ሲሆን ከአምስት ዓመታት በኋላ ይቃጠላል፡፡
ካሲቶችም ይደመሰሳሉ፡፡
ለተሳትፎ የሚሰጥ ክፍያ
ምንም የለም፡፡
ፈቃደኝነት
የጤና ተቓማቱ በዚህ ጥናት እንዲሳተፉ አይገደዱም፡፡ መረጃውንምመከልከል ይችላሉ፡፡
የሚገናኙዋቸው ሰዎች
ጥናቱን በተመለከተ ማናገር ከፈለጉ ዶ/ር ኢስማኤል ዋበላ /ዋና አጥኝ/ በስልክ ቁጥር 0911 648219
እንዲሁም ፕሮፌሰር የማነህ ብርሃን /የጥናቱ አማካሪ/ በስልክ ቁጥር 0911219785 ደውለው መጠየቅ
ይችላሉ፡፡
ይህንን መረጃና የስምምነት ቅጽ አንብበው ከጨረሱና በማንኛውም ሰዓት ጥያቄ እንዲጠይቁ እድሉ
ከተሰጠዎት የተጠቀሰው የሕክምና ተቋም የጥናቱ ተሳታፊ ለመሆን መስማማቱን በፊርማዎ
ያረጋግጡልን፡፡
ስም
የስራ ድርሻ
ድርጅት
ቀን
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Annexe-3 Semi-structured interview with health care workers
Guidelines for semi-structured interviews with health workers (to be adapted for use with
different type of health workers; medical doctors, nurses counselors, pharmacists and social
workers)
Name of facility: ________________________________
Name interviewer: _________________________________
Interview number: _______________________________
Date: ________________________________
Background information on informant (health worker)
a) Sex M/F
b) Age ……..  Years
c) Profession
e) Role in ARV program
f) Involved in program since
Tasks and training
a) What specific training have you received for this job in relation to ARV program? Tell
me about the training (Details)
b) Do you think this training has been sufficient? (Details)
Drugs, treatment and procedures
a) Which treatment guidelines for HIV/AIDS management do you use at this facility?
National ART guidelines………, others……..
If the answer is ‘others’ list down the detail
b) Are the drugs you prescribe always available? Yes……., no……..
If the answer is no; ask details how often? The reason for the stack out and what do you do
about it?
c) How reliable are your lab and diagnostic support services? Do results come in on time?
Yes...…, no……, Details.
d) What is your procedure when a patient is put on ARV drugs for the first time?
Record the detail.
e) What is your procedure when a patient switches regimens?
Record the detail.
f) In what ways are ARV users informed about and prepared for ARV treatment?
g) What kind of information do they receive? Please describe.
 The disease process (e.g. HIV and AIDS)
 How the disease affects the body
 How ARVs work
 How to use them
 The need to continue treatment
 What to do if a pill is forgotten
 Possible interactions with other drugs (including traditional medicines)
 Which side effects can occur & what to do if they occur
 (Breast) feeding requirements
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 When and where to get re supply
Who is giving this information?
Adherence issues
a) Generally speaking do your patients keep their appointments?
b) How do you think your patents do, generally speaking in terms of adherence to ART?
c) Could you estimate the percentage of your patients who you think are sufficiently
adherent to ART? (Respondent gives their definition of sufficiently adherent wheat level
is that?)
d) What do you use to determine adherence
e) We would like to get your views on the following (probe) From your experience
 How would you compare adherence between women and men?
 How would you compare adherences between older patients and younger
patients?
 How does a patient’s educational level affect adherence?
 How do you think that cost to patients influences adherence?
f) How do you think the distance to the health facility affects adherence?
g) From your experience how do you think the following affect adherence?
 Having or not having a treatment support partner?
 Duration of treatment?
 Side effects?
 Lack of food?
 Knowledge about ART?
h) What strategies are in place to monitor adherence?
i) What strategies are in place to support adherence? (Probe family, community
involvement)
j) What are the main challenges you face in supporting your patients to adhere to ARV
drugs?
Challenges and staff support
a) What are the main challenges you and your colleagues face more generally in your
work? (if necessary probe workload stress, burnout)
b) Have you ever been afraid of being infected with HIV through your work?  What were
you specifically afraid about? How do you feel now about the HIV infection risks? Do
you take any extra precautions when working with HIV cases?
c) Have these challenges changed in any way since you started working at the ARV clinic?
d) Is any special support made available for staff engaged in management of HIV/AIDS at
this facility? Yes……, no…….
If no do you think there is a need to have such support?
e) Is there anything you would like to see done differently in this facility? Yes… no…
If yes what?
Is there anything else you would like to tell us or ask us? Yes……, no…….
If yes, please! Provide us the detail
Thank you every much for your participation in this interview.
*The Amharic version is attached on the next page.
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ከጤና ባለሙያዎች ጋር የሚደረግ በከፊል የተዘጋጀ ቃለ ምልልስ
ከጤና ሙያተኞች ጋር የሚደረግ በከፊል የተዘጋጀ ቃለ ምልልስ መመሪያ (ከተለያዩ የጤና
ሙያተኞች አንፃር ማስተካከያ ሊደረግለት ይችላል፡፡)
የጤና ተቋሙ ስም
የጠያቂው ስም
የቃለመጠይቁ ቁጥር
ቀን
የጠያቂው የመደብ ጀርባመረጃ
ሀ ፆታ ወ/ሴ
ለ እድሜ ………… ዓመት
ሐ ሙያ
መ በፀረ ኤች አይ ቪሕክምና ላይ ያላቸውሚና
ሠ በፕሮግራሙ ላይ ያላቸውተሳትፎ የጀመረበት
ስልጠናዎች
ሀ) ከፀረ ኤች አይ ቪ ፕሮግራም አኳያ ምን ስልጠናዎችን ወስደዋል? ዝርዝሩን ቢነግሩን
ለ) ይህ ስልጠና በቂ ይመስልዎታል? ዘርዝሩ
መድሐኒት፣ ሕክምናና የአሰራ ዘዴዎች
ሀ) ለኤች አይ ቪ/ ኤድስ የስራ ሂዳት ምን የሕክምና መመሪያዎችን ይከተላሉ? ብሄራዊ የኤ.አር.ቲ
መመሪያ………….. ሌሎች……………..
መልስዎ "ሌሎች" ከሆነ ይዘርዝሩ
ለ) የሚያዟቸው የፀረ ኤች አይ ቪመድሃኒቶችሁሌም በተቋሙውስጥ ይገኛሉ?
ይገኛሉ አይገኙም
መልስዎ አይገኙም ከሆነ፣ መቼ መቼ? እንደጠፉ ጠይቅ፣ የጠፉበትን ምክንያትና የተወሰዱትን
እርምጃዎችጠይቅ
ሐ) የላብራቶሪና የሌሎች ምርመራ አገልግሎቶች ምን ያሕል አስተማማኝ ናቸው? ውጤቶች በጊዜ
ይደርሳሉ?
አዎ አይደለም ዘርዝሩ
መ) አንድ በሽተኛ በፀረ ኤች አይ ቪ መድሃኒት ላይ ሲቀመጥ የሚከተሉትን የአሰራር ሂደት
ይዘርዝሩ፡፡
ሠ) አንድ የኤች አይ ቪ ታካሚ መድሃኒቶቹን መለወጥ ካስፈለገ የሚከተሉትን የአሰራር ሂደት
ይዘርዝሩልን?
ረ) የፀረ ኤች አይ ቪ ተጠቃሚዎች መድሃኒት ከመጀመራቸው በፊት በዝግጅት ወቅት ሊያደርጉ
የሚገባቸውንና እናንተ የምትነግሩዋቸውን በሙሉይዘርዝሩልን፡፡
ሰ) የፀረ ኤች አይ ቪ ተጠቃሚዎች ምን መረጃዎችን ያገኛሉ? እባክዎን ከዚህ በታች ከተዘረዘሩት
አንፃር ያብራሩልን፡፡
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 የበሽታው ሂደት (ምሳሌ ኤች አይ ቪና ኤድስ)
 በሽታው ሰውነትን እንዴት እንደሚጎዳ
 የፀረ ኤች አይ ቪመድሃኒት እንዴት እንደሚሰራ
 የፀረ ኤች አይ ቪመድሃኒት አጠቃቀም
 የፀረ ኤች አይ ቪሕክምና ቀጣይነት
 መድሃኒቱ ተረስቶ ባይወሰድምንመደረግ አለበት
 ከሌሎች መድሃኒቶች ጋር ያለው የድርጊት ትስስር (Interaction) (የባህላዊ መድሃኒቶችን
ጨምሮ)
 ምን የጎንዮሽውጤቶች (Side Effects) ይከሰታሉ? ከተከሰቱስ ምን እርምጃ ይወሰዳል፡፡
 ስለ እናትጡት አስፈላጊነት
 የመድሃኒት አቅርቦትመቼና ከየት እንደሚገኝ፤ ስለ አቅርቦቱመረጃ የሚሰጠውማነው?
የፀረ ኤች አይ ቪመድሃኒት ቁርኝት (Adherence) ጉዳይ፡-
ሀ) በአጠቃላይ ለመናገር በሽተኞችዎ ቀጠሮአቸውን ያከብራሉን?
አዎ አይደለም
ለ) የመድሃኒቱን ቁርኝት በተመለከተ በሽተኞችዎ እያደረጉ ያለውን ቢገልፁልን?
ሐ) በርስዎ ግምትምን ያህሉ በሽተኞች (በመቶኛ) በቂ ቁርኝት አድርገዋል?
መ) የቁርጭት ሁኔታን ለመወሰን ምን ዘዴዎችን ይጠቀማሉ? (ቆርቁር- ቀጠሮዎችን፣ የመድሃኒት
እደላዎችን እና ወዘተ)
ሠ) ከልምድዎ አንፃር ስለሚከተሉትሁኔታዎችማወቅ እንፈልጋለን፡፡
 በሴቶችና በወንዶችመካከል ያለውን የመድሃኒት ቁርኝት እንዴት ያወዳድሩታል?
 በዕድሜ በገፉና በወጣቶችመካከል ያለውን የመድሃኒት ቁርኝት እንዴት ያወዳድሩታል?
 የበሽተኛዎ የትምህርት ደረጃ በቁርኝት ላይ ምን ተፅዕኖ ይኖረዋል?
 በሽተኛዎ ለምግብ ለመጓጓዣና ለመሳሰሉት የሚያወጣው ወጪ በቁርኝት ላይ ምን ተፅዕኖ
ይኖረዋል?
 ለጤና ተቋሙ ያለው ርቀት በቁርኝት ላይ ምን ተፅዕኖ ይኖረዋል?
ረ/ ከልምድዎ አንፃር የሚከተሉት በቁርኝት ላይ የሚኖራቸውተፅዕኖ ምን ይመስልዎታል?
 የሕክምና አጋዥ /ደጋፊ/መኖር አለመኖር?
 በሕክምና ላይ የቆዩበት ጊዜ?
 የመድሃኒት የጎንዩሽውጤቶች?
 የምግብማጣት?
 ስለ ኤ አርቲ ያለው እውቀት?
ሸ/ ቁርኝትን ለመከታተልምን የተዘረጉ ሰትራቴጂዎች አሉ?
ቀ/ በሽተኞችዎ ከፀረ ኤች አይ ቪ መድሃኒቶች ጋር እንዲቆራኙ በሚያደርጉት ድጋፍ ያጋጠሞት
ፈትና /እክል/ምንድን ናቸው?
እክሎችና የሙያተኛ ድጋፍ
ሀ/ በስራችሁ ላይ እርስዎና የሙያ አጋርዎችዎ ይጋጠማችሁ ዋና ዋና እክሎች ምንድን ናቸው?
/አስፈላጊ ከሆነ የስራጫናሁኔታን ቆርቁር/
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ለ/ በስራ ላይ በኤች አይ ቪ ልበከል እችላለሁ ብለው ፈርተው ያውቃሉ? የፈሩት የትኛውን ነበር? አሁን
በስራ ላይ ሊኖር የሚችለውን በኤች አይ ቪ የመበከል ስጋት እንዴት ያዩታል? የኤች አይ ቪ
በሽተኞችን በሚያክሙበተ ጊዜ የሚከተሉት የተለየ ጥንቃቄ አለ?
ሐ/ እነኚህ ከላይ የጠቀሱዋቸው እክሎች በጊዜሒደት ተለውጠዋል?
መ/ በዚህ ተቋምውስጥ በኤች አይ ቪ/ኤድስ የስራሒደት ላይ ለሚሰሩሙያተኞች የተለየ ድጋፍ አለ?
አዎ የለም
መልሱ የለም ከሆነ ለነኚህሙያተኞች የተለየ ድጋፍ ያስፈልጋል ይላሉ፡፡ /ዝርዝሩን ቆርቁር/
ሠ/ በዚህ የጤና ተቋምውስጥ በተለየ ሁኔታ ተሰርቶማየት የሚፈልጉት አለ?
አዎ የለም መልሱ አዎ ከሆነ ምን?
ረ/ ሌላ የሚነግሩን ወይም የሚጠይቁን ነገር አለ? አዎ የለም
መልሱ አዎ ከሆነ ዝርዝሩን ይንገሩን
ለዚህ ቃለመጠይቅ ስላደረጉልን ትብብር ከልብ እናመሰግኖታለን፡፡
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Annex: 4 Semi-structured interviews with ARV users
Name of the interviewer ____________________________
Interview number ____________________________
Name of health facility _____________________________
Date _____________________________
 Greeting (to create rapport with ARV user)
 Statement of confidentiality
1.  Socio-demographic  information on informants
a) Sex, M…., F…….
b) Age,………years
c) Educational level (no education , primary, secondary, tertiary)
d) Who do you live with (spouse, children, house girl/partner, relatives, etc?)
e) Employment  status ( unemployed, self, government, NGO)
f) Distance  from facility (in time or distance)……KM, or….Hour(s)
We would like to understand a bit about how it is for people taking ARVs, Could you tell me
how you spend a normal day? How do you spend your spare time? What do you do to relax?
2.  Medical history of patient
a) When where you first diagnosed?
b) What made you decide to go for testing?
c) When did  you start treatment for HIV (ART)
d) How do you feel about your health since you started treatment? How would you describe
your health since you started treatment?
 Better
 The same
 Worse
3.  Patient knowledge about HIV\AIDS
We would like to understand what people actually know about the illness that they have. Can
you tell me what you know about HIV\AIDS? (Allow patient to say what they want, then probe
on the following; cause of HIV infection, cause of AIDS, prevention, life-long infection).Apart
from this, is there anything else you may have heard from your community that explains AIDS in
a different way?
4. Patient knowledge about ARVs
We would like to understand what people know about their treatment. Could you help us with
this by telling me what you know about ARVs? (Allow patient to say what they want, then probe
on the following: Prolongs life, Improves quality of life, life long treatment, Knowledge about
side effects.)
5. Assessment of adherence and non-adherence
We are trying to find out how patients manage to take their medicines, for some people it’s not a
problem but we also know that others don’t always find it easy. Please feel free to be open about
the problems you face with this. Everything you say here will remain confidential, and will not
be shared with anyone at the clinic.
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a) Are there any other medications, other than ARVs you are taking (e.g. co-trimoxazole, herbs
etc)
b) Did you perhaps miss any of your ARVs in the past seven days? Yes…., no……
(Confirm in sympathetic manner. Details if yes)
c) This is a very important question. We appreciate how difficult it can be to take pills on a
daily basis. If you sometimes miss a dose please can you tell me what causes this to happen?
Can you give an example or two?
d) On the other hand, what is it that helps you to take your pills regularly and on time? (e.g.
organizations, individuals, clock etc)
e) Have you disclosed your status to any one? Yes…... no……
If yes, who? Do they help you to take your pills? (If not covered in (f)
f) Have you had your treatment changed at any moment since you started on ART? If yes,
why? (e.g. Treatment failure, side effects)
g) Have you ever missed an appointment at your ART clinic? Yes…., no….
If yes reasons, and details on type of consultation, review /refill etc
h) What do you think happens in your body if you skip your ARV medication?
i) Have you ever thought about stopping ART? Yes……, no…….
If yes, details.
6. Perception about HIV/AIDS, ARVs and stigma
Have you had any experience of being treated differently because of your HIV status?
7. Cost considerations
a) How much do you have to pay to cover your travel expenses when you visit the clinic?
b) What is the cost of registering at the clinic (if any)?
c) What is the cost of the ARV medicines that you take (if any)?
d) Do you lose any income as a result of your coming to the clinic?
e) Do you incur any other costs as a result of your taking ART?
8. Quality of care
a) What do you think of the service you receive at this clinic? (General, open ended and then
probe as below ask for details as necessary)
 Do you feel listened to?
 Are you given the chance to state your problems and ask questions?
 Are you treated with respect
 Do you feel you can trust the health workers?
 Do you have privacy during consultation and counseling?
 How do you find the environment of the clinic?
b) How long did you have to wait before being attended to?
9. Perceived problems and possible solutions
a) What do you perceive as the biggest problem regarding taking ARV treatment?
b) What do you think could be done to improve this?
*The Amharic version is attached on the next page.
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ከፀረ ኤች አይ ቪ ተጠቃሚዎች ጋር የሚደረግ በከፊል የተዘጋጀ ቃለ ምልልስ፡፡
የጤና ተቋሙ ስም
የጠያቂው ስም
የቃለመጠይቁ ቁጥር
ቀን
በቀድሚያ ሰላምታ
የመተማመኛውን ቅጽ በርጋታማንበብ
1. የተጠያቂው የማሕበራዊና ስነ ሕዝባዊመረጃ
ሀ/ ፆታ ወ ሴ
ለ/ እድሜ አመት
ሐ/ የትምህርት ደረጃ /አልተማሩም፣ 1ኛ ደረጃ፣ 2ኛ ደረጃ፣ ከፍተኛ/
መ/ ከማን ጋር ይኖራሉ /ከባለቤትዎ፣ ከልጆችዎ፣ ካላገቡት፣ ከዘመድ ወዘተ?/
ሠ/ የቅጥር ሁኔታ /ያልተቀጠሩ፣ የግል፣ የመንግስት፣ የመያድ/
ረ/ የጤና ተቋሙርቀት /በጊዜ ወይም በርቀት/ ኪ.ሜ ሰአት
2. የበሽተኛው የሕክምና ታሪክ
ሀ/መቼ ነበር ኤች አይ ቪ የተገኘቦት
ለ/ ለመመርመር እንዲወስኑ ያደረጎት ምን ነበር?
ሐ/ የፀረ ኤች አይ ቪመቼ ጀመሩ?
መ/ ሕክምናውን ከጀመሩ በኋላ የጤንነትዎ ሁኔታ እንዴት ይሰማዎታል? መድሃኒት ከጀመሩ በኋላ
ያለዎትን የጤንነት ሁኔታ እነዴት ይገልፁታል?
. ተሻሽሏል
. ለውጥ የለውም
. ተባብሷል
3. በኤች አይ ቪ/ኤድስ ላይ ያለው የበሽተኛው እውቀት
ሰዎች ስለአላቸው በሽታ ምን ያህል ያውቁ እንደሆነ ልንረዳ እንሻለን፡፡ ስለ ኤች አይ ቪ/ኤድስ
የሚያውቁትን ሊነግሩኝ ይችላሉ? /በሽተኛው የፈለገውን እንዲናገር ፍቀድለት፡፡ በመቀጠለም በኤች
አይ ቪ መንስኤዎች፣ በኤድስ ምክንያቶች፣ በሽታን በመከላከል፣ ስለ እድሜ ልክ ሕመም ቆርቁር፡፡
ከዚህ ሌላ ከማሕበረሰቡ ኤድስን በተለየመንገድ ሲገለፅ የሰሙት ካለ?/
4. በፀረ ኤች አይ ቪመድሃኒት ላይ የበሽተኛው ዕውቀት
ሰዎች ስለ ሕክምናቸው የሚያውቁትን መረዳት እንሻለን፡፡ ይህን በተመለከተ ስለ ኤች አይ ቪ
የሚያውቁትን ለኔ በመንገር ሊረዱኝ ይችላሉ? /በሽተኛዎ የፈለጉትን እንዲናገሩ ፍቀድላቸው፣
በመቀጠልም፤ ሕይወት ያረዝማል፣ የኑሮን ሁኔታ ያሻሽላል፣ የእድሜ ልክ ሕክምና፣ የጎንዮሽ
የመድሃኒትውጤቶች እውቀት ላይ ቆርቁር/
5. የቁርኝት ወይም የቁርኝት አልባ ግምገማ፡፡
በሽተኞች መድሃኒታቸውን እንዴት እንደሚወስዱ ለመፈተሽ እንሞክራለን፡፡ ለአንዳንዶቹ ይህ ችግር
አይደለም፡፡ ለሌሎች ደግሞ ቀላል እንዳልሆነ እናውቃለን፡፡ እባክዎ ከዚህ አንፃር ያጋጠሞትን ችግር
በግልፅ ለማናገር ነፃ ይሁኑ፡፡
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ሀ/ ከፀረ ኤች አይ ቪ መድሃኒት ሌላ የሚወስዱት መድሃኒት አለወይ? /ምሳሌ ኮትረይምክሳዞል፣
የአበሻመድሃኒት /ሰራስር፣ ቅጠላ ቅጠል… / እና ወዘተ/
ለ/ ይህ በጣም ጠቃሚ ጥየቄ ነው፡፡ መድሃኒቶችን ሳያቋርጡ በየቀኑ መውሰድ አዳጋች መሆኑ
ይሰማናል፡፡ አንዳንዴ መድሃኒቶችን ከረሱ፣ የረሱበት ምክንያቶች ምን ምን ናቸው? አንድ
ወይምሁለትምሳሌዎችሊሰጡኝ ይችላሉን?
ሐ/ በሌላ አንፃር፣ መድሃኒቶችን በትክክልና በወቅቱ እንዲወስዱ የረዳዎት ምንድን ነው? /ምሳሌ
ድርጅቶች፣ ግለሰቦች፣ ሰአት፣ ደወል ወዘተ/
መ/ በኤች አይ ቪመያዝዎን ለሌላ ነግረዋልን? አዎ……………. አልነገርኩም………….
መልስዎ አዎ ከሆነ ለማን? እነኚህ የነገሯቸው ሰዎች መድሃኒትዎን አስታውሰው እንዲወስዱ
ረድተዎታልን?
ሠ/ የፀረ ኤች አይ ቪ ሕክምና ከጀመሩ ወዲህ የፀረ ኤች አይ ቪ መድሃኒቶች የተለወጡበት ወቅት
ነበር? አዎ የለም መልስዎ አዎ ከሆነ፣ ለምን ተለወጡ?
/ለምሳሌመድሃኒቶቹ ባለመሰራታቸው፣ በመድሃኒቱ የጎንዮሽውጤቶች/
ረ/ በኤ አር ቲ ቀጠሮ ቀን ቀርተው ያቃሉ አዎ የለም መልስዎ አዎ ከሆነ
የቀሩበት ቀጠሮምን ነበር /ለምሳሌ ሐኪምዎን ለማማከር፣መድሃኒት ለመውሰድ ወዘተ/
ሰ/ መድሃኒትዎን በትክክል ካልወሰዱ በራስዎ ሌላ ምን ችግር ሊያመጣብዎት ይችላል ብለው
ያስባሉ?
ሸ/ የፀረ ኤች አይ ቪመድሃኒትዎን አቆማለሁ ብለው አሰበው ያውቃሉ? አዎ
የለም መልስዎ አዎ ከሆነ በዝርዝር ያስረዱን
6. በኤች አይ ቪ በፀረ ኤች አይ ቪመድሃኒቶችና፣ በመገለል ዙሪያ ያሉ ግንዛቤዎች
በኤች አይ ቪ በመያዝዎ ሰበብ ከሌሎች ተለይተው የታዩበት አጋጣሚ ይኖር ይሆን?
/በቤተሰብዎ፣ በስራ ቦታዎ በሌሎች ቦታዎች፣ አዎ የለም መልስዎ አዎ ከሆነ
በዝርዝር ያስረዱን
7. የክፍያ ሁኔታ
ሀ/ ወደ ክሊኒኩ በሚመጡበት ጊዜ ለመጓጓዣምን ያህል ይከፍላሉ?
ለ/ በቀጠርዎ ቀን ለሌላ ጉዳይ የሚያወጡትወጪይኖራልን? /ለምሳሌ ለምግብ/
ሐ/ ለክሊኒኩ ለምዝገባ ይከፍላሉ? አዎ የለም መልስዎ
አዎ ከሆነ ሰንት ይከፍላሉ
መ/ ክሊኒክ በመምጣትዎ ሰበብ የሚቀርቦት ገቢ ይኖራልን?
ሠ/ የፀረ ኤች አይ ቪመድሃኒት በመውሰድዎምክንያት ለሌላ ወጪተዳርጌአለሁ ይላሉ?
ረ/ እራስዎ ወይም ቤተሰብዎ መድሃኒትዎን በወቅቱ እንዲወስዱ በማስቻላችሁ መስዋዕት
ያደረጋችሁት ነገር ይኖራል፡፡ /ለምሳሌ የስራ ጊዜ፣ የዕንቅልፍ ሰዓት ወዘተ/
8. የእንክብካቤ ጥራት
ሀ/ በዚህ ክሊኒክ ውስጥ ስለሚሰጥዎት አገልግሎትምን ያስባሉ? /አጠቃላይ፣ ክፍት የሆነ/ በመቀጠል
በሚከተሉት ላይማብሪሪያ ጠይቅ
 የጤና ተቋሙ ሰራተኞች ችገሬን ይሰሙኛል ይላሉ?
 ችግርዎን እንዲገልፁና ጥያቄዎች እንዲጠይቁ እድል የሰጦታል?
 በአክብሮት ይቀበሎታል፣ በአክብሮት ያስተናግዶታል፣ በአክብሮት ይሸኛሉ፡፡
 የጤናሙያተኞች ላይ እምነት አለኝ የሚል ስሜት አሎት?
 በምርመራወይም በምክክር አገልግሎት ወቅት ነፃነትዎ /Privacy/ ይጠበቃል?
 የክሊኒኩን ሁኔታ እንዴት አገኙት?
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ለ/ ገብተው እስከሚስተናገዱምን ያህል ጊዜመጠበቅ ይኖርቦታል?
8. የችግሮች ግንዛቤናመፍትሄዎቻቸው
ሀ/ በፀረ ኤች አይ ቪ አወሳሰድ ዙሪያ ያለውትልቁ ችግር ምን ይመስሎታል?
ለ/ እነኚህን ችግሮች ለመቅረፍምንመደረግ አለበት ይላሉ?
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Annex-5 Guide for observation of health facility
Name of observer ___________________________
Name of health facility _____________________________
Date/time observation took place __________________________
This observation shall be conducted by the researcher.
The purpose is to give a descriptive of the setting under which care takes place
1. Describe hospital setting in general.
2. Describe the location and setting of the ARV clinic and support services (pharmacy,
laboratory, social welfare /counseling).
3. Describe the sanitary condition of the environment, how clean or dirty is it, check out the
toilets. Describe
4. Where are patients received? Is there privacy? Describe what you see
5. What is the general attitude of health workers, are they receptive and willing to assist
clients or are they impatient? Describe what you see what notices or informations are
displayed for clients to read and/or see.
6. Specifically look through where patients get ARVs to see if there is any piece of
information emphasizing the need for good adherence or telling people how to improve
adherence.
*The Amharic version is attached on the next page.
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የጤና ተቋሙ የምልከታ (Observation) መመሪያ
የተመልካቹ ስም
የጤና ተቋሙ ስም
ምልከታው የተደረገበት ቀንና ሰአት
ይህ ምልከታ በተመራማሪውሊደረግ ይችላል፡፡
አላማው የግልጋሎትመስጫውን ነባራዊ ገፅታ ለማመላከት ነው፡፡
1. በአጠቃላይ የጤና ተቋሙን ነባራዊ ሁኔታ ግለፅ
2. የፀረ ኤች አይ ቪ መስጫ ክሊኒኩን አቀማመጥና ነባራዊ ሁኔታ ግለፅ /ፋርማሲ፣ ላብራቶሪ፣
የምክክር አገልግሎትመስጫ/
3. የአካባቢውን የንፅህና ሁኔታ ግለፅ፣ ምንያህል ንፁህ ወይም ቆሻሻ እንደሆነ፣ ሽንት ቤቶችን
ፈትሽ፣ በዝርዝር ግለፅ
4. በሽተኞች የትነው አቀባበል የሚደረግላቸው? ነፃነት /Privacy/አለው? ያየኸውን ዘግብ
5. የጤናሙያተኞቹ አጠቃላይ ዝንባሌ /Altitude/ ምን ይመስላል? እንግዳ ተቀባይና በሽተኞችን
ለመርዳት ፈቃደኞች ናቸው? ለእይታ ወይም ለንባብ የተመቻቹ ማስታወቂያዎች ወይም
መረጃዎች ካሉ ገልፀህ ዘግብ
6. በሽተኞች የፀረ ኤች አይ ቪ መድሃኒት የሚያገኙበትን ቦታ ተመልከት፣ በመድሃኒት
መስጫው ክፍል ስለመድሃኒት ቁርኝት በቂመረጃመሰጠቱን ዘግብ
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Annex-6 Observation of consultation with health workers
Study no
(Medical Doctor, Health Officer, Nurse, Pharmacist/Druggist, Social worker/ Counselor,
laboratory personnel)
Guide has to be adapted taking in to account the type of consultation to be observed
(Don’t’ forget informal unstructured observations!!!)
Name of facility ______________________________
Date ______________________________
Interviewer ______________________________
Consultation Start time ____   End time ____
Observation of consultation with ________________________________
 Medical doctor
 Health Officer
 Nurse
 Social worker/counselor
 Pharmaceutical staff
 Laboratory personnel
 Other
1. Background information on informant
a) Sex M/F
b) Age ….. Years
2. Reason / Aim of the consultation :
 Counseling
 Initiation of active ARV treatment
 Routine follow up
 Other reason
3. Is patient well received? Yes                    No
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(If not, describe)
_________________________________________________
4. Was the client greeted in a friendly manner?    Yes               No
5. Does the consultation take place in privacy?     Yes              No
6. Does the health worker ask about any symptoms?  Yes             No
7. Is the patient invited to ask questions?                Yes                 No
(If yes, what do they ask? Was the questions addressed?) Details:
8. Is the patient told what to do next (within the health facility)?
Is the patient told where to go for that?                                                      Yes           No
9. Is the sequence of events in relation to treatment protocols explained to new patients?
(Requires training for observer)                                                             Yes             No
10a. If new patients do they receive comprehensive general information about ARVs?
(Tick if covered,):
 How ARVs work
 How to use them
 The need to continue treatment
 What do if a pill is forgotten/ missed
 Possible interactions with other drugs, including traditional medicines
 Which side-effects (for the different drugs) may occur
 What to do if they occur
 (Breast) feeding requirements
 When and where to get re-supply
 Requirement to bring unused medicines
10b. Are patients (especially new and those switching regimens) given the following
information about ARVs (Tick if covered).
 Dosage (number of  tablets to take and how often)
 Times of when to take the medicines
 How to take them in relation to meals (where necessary)
 What to do if vomit the pill
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 What to do if forgets  medicine on time
 what to do if dose is missed
 What to do if traveling?
10c. For follow up users only
Does the health worker ask if the patient missed a dose?                   Yes             No
If yes, does the health worker explain the effects of missing dose?   Yes              No
Does the health worker offer support to not miss the does?     Yes                 No
If yes, describe                                                                            Yes               No
___________________________________________________________________
11. Did the provider listen carefully to the client?                                            Yes                No
12. Was any written information given? (new patients) If yes, bring a copy of
it if possible. Yes                  No
13. For follow up patients only
Does the health worker count the patient’s pills before giving                   Yes                   No
him/her a new supply?
14. Does the health worker ask the patient if they are taking                         Yes                  No
any other medicines
15. Does the patient receive specific tools to remind them to take their medicines? Yes            No
*The Amharic version is attached on the next page.
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የጤናሙያተኞች በስራ ላይ እይታ
የጥናት ቁጥር
/የሕክምና ዶክተር፣ የጤናመኮንን፣ ነርስ፣ የፋርማሲ ባለሙያ፣ አማካሪ፣ የላብራቶሪ ባለሙያ/
እንደስራው ሁኔታ መመሪያው ሊስተካከል ይችላል፡፡ /መደበኛ ያልሆነ ያልተዘጋጀ እይታ ሊኖር
እንደሚችል አትርሳ/
የጤና ተቋሙ ስም
ቀን
ጠያቂው
የሕክምና ስራው የተጀመረበት ሰአት፣ ያለቀበት ሰአት
የሕክምና ስራውምልከታ ከ
- የሕክምና ዶክተር
- የጤናመኮንን
- ነርስ
- አማካሪ
- የፋርማሲ ባለሙያ
- የላብራቶሪ ባለሙያ
- ሌሎች
1. የተጠያቂው የመደብ ጀርባመረጃ
ሀ/ ጾታ
ለ/ እድሜ
ወ/ሴ
…………… ዓመት
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2. ምክንያቶች/የሕክምናው አላማ
. ለምክክር
. የፀረ ኤች አይ ቪመድሃኒት ለማስጀመር
. የተለመደ ክትትል
. ሌሎችምክንያቶች
3. በሽተኛው በመልካም አቀባበል ተስተናግዶል?
አዎ የለም
4. ደንበኛው/በሽተኛው/ በወዳጅነትመንፈስ ሰላምታ ተሰጥቶታል?
አዎ የለም
5. የሕክምና ስራው በነፃነት /Privacy/ ነው የተካሄደው?
አዎ የለም
6. የጤና ባለሙያው ስለ በሽታውምልክቶችታካሚውንጠይቋል?
አዎ የለም
7. በሽተኛውጥያቄ እንዲጠይቅ ተጋብዟል?
አዎ የለም
መልሱ አዎ ከሆነ፣ ምን ጠየቀ?
ጥያቄው በትክክል ተስተናግዷል? ዘርዝር
8. በጤና ተቋሙውስጥ በሽተኛው ቀጥሎምን እንደሚያደርግ ተነግሮታል? አዎ የለም
ከተነገረው ለዚህ ጉዳይ ወዴትመሄድ እንዳለበት ተነግሮታል?
አዎ የለም
9. ለአዲስ በሽተኞች ስለ ሕክምናውሁኔታ በቅደም ተከተል ተነግሮአቸዋል?
አዎ የለም
/ተመልካቹ ስልጠና ያሰፈልገዋል፡፡/
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10ሀ. አዲስ በሽተኞች ከሆኑ ስለ ፀረ ኤች አይ ቪ መድሃኒቶች የተጠቃለለና የተሟላ መረጃ
ተሰጥቶአቸዋልን?
/ከተካተተ ምልክት አድርግ ካልተካተተ 0ምልክት አድርግ/
. ፀረ ኤች አይ ቪመድሃኒቶች እንዴት እንደሚሰሩ
. ፀረ ኤች አይ ቪመድሃኒቶችን እንዴትመጠቀም እንደሚቻል
. ስለ ሕክምናው ቀጣይነት አስፈላጊነት
.መድሃኒቱ ቢረሳ ወይም ቢዘለል ምንመደረግ አለበት
. የፀረ ኤች አይ ቪመድሃኒት ከሌሎችመድሃኒቶች ጋር /የባሕላዊመድሃኒቶች/
ጨምሮ ያለውኢንተርአክሽን /Interaction/
. በተለያዩ የፀረ ኤች አይ ቪመድሃኒቶችምን ምን የተለያዩ የጐንዮሽውጤቶች
ሊከሰቱ ይችላሉ
. ከተከሰቱምንመደረግ አለበት
. የናትጡትወተት አስፈላጊነት
.መድሃኒቶችን ለማግኘትመቼና የትመሄድ አለበት
. ያልተጠቀሙትንመድሃኒት ወደ ሕክምና ተቋሙ ስለማምጣት አስፈላጊነት
10ለ. ለበሸተኞች /በተለይ አዲስና መድሃኒት የተለወጠላቸው/ የሚከተሉትን መረጃዎች
ተሰጥቷቸዋልን?
ከተካተተ ምልክት አድርግ፣ ካልተካተተ 0ምልክት አድርግ
. ስለመድሃኒት አወሳሰድ /Dosage/ /ምን ያሕልመድሃኒቶች በቀን ስንት ጊዜ እንደሚወስዱ/
.መድሃኒቶቹ የሚወሰዱበት ሰአት
. አወሳሰዳቸው ከስርአተ አመጋገብ ጋር ያለው ተዛምዶ /አስፈላጊ ከሆነ/
.መድሃኒቱ ካስመለሳቸውምን ይደረጋል
.መድሃኒቱን በሰአትመውሰድ ከተረሳ ምን ይደረጋል
.መድሃኒቱ ሳይወሰድጭራሽ ከተረሳ ምንመደረግ አለበት
. በጉዞ ወቅትምንመደረግ አለበት
10ሐ. ተከታታይሕክምና ላይ ላሉ ብቻ
የጤና ባለሙያው በሽተኛውመድሃኒቱን ረስቶ እንደሆነ ጠይቆታልን?
አዎ አይደለም
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መልሱ አዎ ከሆነና በሽተኛው አዎ መድሃኒቱን ረስቼ ነበር ካለ የጤና ባለሙያው መድሃኒቱን
ባለመውሰዱምክንያት ሊከተል የሚችለውን ችግር አብራርቶለታልን?
አዎ የለም
መልሱ አዎ ከሆነ በዝርዝር ዘግብ
11. የጤና ባለሙያው ደንበኛውን /በሽተኛውን በጥሞና አዳምጦታልን?
አዎ የለም
12. በተለይ ለአዲስ ታካሚዎች የፅሁፍመረጃ ተሰጥቶአቸዋልን?
አዎ የለም መልሱ አዎ ከሆነ ከተቻለ ኮፒውን አምጣ
13. በተከታታይሕክምና ላይ ላሉ በሽተኞች ብቻ
የጤና ባለሙያው ሌላ አዲስ መድሃኒት ከመስጠቱ በፊት ያለፈውን ወር መድሃኒት በትክክል
መውሰዱን ቆጠራ አድርጓል /Pill Count/ አዎ የለም
14. የጤና ባለሙያው በሽተኛውሌሎችመድሃኒቶችንመውሰዱን ጠይቋልን?
አዎ የለም
15. በሽተኛውመድሃኒቱን በትክክል እንዲወስድ የሚያግዙ ዘዴዎች ተነግሮታልን?
አዎ የለም
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Annex-7 Questionnaire guidelines for key informant interview
Criteria
 Key informants will be identified from among the communities to which the ARV users
belong (e.g. Leaders of PLH associations)
 Adults 18 years of age and above
 One moderator, one note-taker (and use of tape recorder)
 Neutral venue in the community
The following issues should be addressed before commencing the interview
 Short introductory remarks
 Explain the purpose of the study
 Define what we mean by ‘adherence’
 Purpose of this discussion
 Reassurance about confidentiality
Session-1 Introduction of researchers and participants
Session -2 Interview
1. Do you know where people can obtain ARVs in this area? (Probe also perception on
ART, availability of traditional healers in that area, etc)
2. How does your community view for people who are taking ART? (Probe on Stigma and
discrimination, logistical issues for reaching to the health institution, etc)
3. Do they face any problems with adherence to their medication? ( Probe on poverty,
hunger, access to ART, etc)
4. What activities take place at the moment in your community to help people adhere to
their medication? (Probe on support, home based care, etc)
5. What should be done to insure that people on ARVs take their medications as instructed?
Duration of discussion (1 ½ hours)
Conclusion, thank participants
*The Amharic version is attached on the next page.
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ለቁልፍመረጃመጋቢዎች የተዘጋጀ ቃለ ምልልስመመሪያ
መመሪያ
. ቁልፍ መረጃ መጋቢዎች ከፀረ ኤች አይ ቪ መድሃኒት ተጠቃሚዎች ማሕበረሰብ ውሰጥ
ይመረጣሉ፡፡ /ለምሳሌ ከኤች አይ ቪ ጋር ከሚኖሩማህበሮች፣/
. 18 አመት ወይም ከዚያ በላይ የሆነ
. አንድ አስተባባሪ፣ አንድ ዘጋቢ /ቴፕ ሪኮርደርመጠቀም/
. ገለልተኛ የሆነ ለቃለ ምልልስ አመቺ የሆነ ቦታ
ቃለ ምልልሱን ከመጀመራችን በፊት የሚከተሉት ጉዳዮችመተግበር አለባቸው፡፡
. አጭር የመግቢያመግለጫ
. የጥናቱን አላማማብራራት
. ቁርኝት /Adherence/ ስንል ምንማለታችን እንደሆነመግለፅ
. የዚህውይይት አላማ
. ስለሚስጥራዊነቱመተማመኛመስጠት
ክፍል 1 የተመራማሪዎቹና የጥናቱ ተካፋይ ትውውቅ
ክፍል 2 ቃለ ምልልስ
1. በዚህ አካባቢ ሰዎች የፀረ ኤች አይ ቪመድሃኒት ከየት እንደሚያገኙ ያውቃሉ?
/ስለ ኤ አር ቲ በሕብረተሰቡ ውስጥ ያለው አመለካከት፣ የአገር ባሕል ሕክምና ሰጪዎች እና
የሌሎችም በአካባቢው የመኖር ሁኔታን ቆርቁር/
2. የፀረ ኤች አይ ቪ መድሃኒት የሚወስዱ ሰዎችን ሕብረተሰቡ እንዴት ይመለከታቸዋል? /ስለ
አድልዎናመገለል፣ ወደጤና ተቋማት ለመድረስ ያለውን ችግርና የመሳሰሉትን ቆርቁር/
3. ታካሚዎች በፀረ ኤች አይ ቪ መድሃኒት ቁርኝት አንፃር የሚገጥማቸው ችግር ይኖራልን?
/በድህነት፣ በረሃብ፤ በኤአርቲ ተቋማትና በሌሎች የቁርኝትምክንያቶች ዙሪያ ቆርቁር/
4. በአሁኑ ጊዜ በአካባቢው ታካሚዎች ከመድሃኒቱ ጋር በበቂ እንዲቆራኙ ምን ምን ተግባራት በስራ
ላይ ውለዋል? /ስለ ሕክምና አጋዥ (treatment support) ስለ ቤት ለቤት እንክብካቤና ስለመሳሰሉት
ቆርቁር/
5. ታካሚዎች የፀረ ኤች አይ ቪ መድሃኒት በታዘዘላቸው መሰረት እንዲወስዱ ምን መደረግ አለበት
ይላሉ
የውይይት ጊዜ 1ሰአት ከ30 ደቂቃ
ማጠቃለያ
ተሳታፊውን አመስግን፡፡
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